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SUMMARY 
The effect of antiamoebic agents on human corneal cells and the 
Acanthamoeba castellanii 1BU strain  
 
Background: Acanthamoeba keratitis is a progressive, sight-threatening disease. The correct 
diagnosis is often delayed for the patients. In an early stage, ophthalmologists observe 
pseudodendritiformic epitheliopathy, “dirty epithelium”, spot-like multifocal stromal 
infiltrates and radial perineuritis. Later on, a ring infiltrate develops and in long-standing, 
recalcitrant Acanthamoeba keratitis, uveitis, retinal vasculitis and scleritis may occur and 
result in blindness. Since AK presents with heterogeneous clinical appearance and low 
incidence, there have been no clinical trials comparing different treatment modalities in this 
disease and no standardized treatment of AK has been established, yet. The lack of a 
standardized therapy against AK is also in part due to the lack of a generally agreed drug 
testing regime against Acanthamoeba. 
Therefore, we had the following purposes: 
⚫ Histological analysis of two Acanthamoeba keratitis eyes with anterior and posterior 
segment inflammation and blindness. 
⚫ To analyze the effect of biguanides (polyhexamethylen biguanid (PHMB), chlorhexidine 
(CH)) and diamidines (hexamidine-diisethionat (HD), propamidin-isethionate (PD), 
dibromopropamidine-diisethionat (DD)) on human corneal epithelial cell, keratocyte and 
endothelial cell viability, proliferation and migration, in vitro. 
⚫ To compare LDH release assay, trypan blue and fluorescent stainings and non-nutrient 
Escherichia coli (E. coli) plate assay in determining treatment efficacy of 
antiamoebic-agents against Acanthamoeba castellanii trophozoites and cysts, in-vitro. 
⚫ To analyze the concentration dependent effect of biguanides (PHMB, CH); diamidines 
(HD, PD, DD); natamycin (NM); miltefosine (MF); povidone iodine (PVPI) and chlorin 





• Two eyes of 2 patients (age 45 and 51 years) with Acanthamoeba keratitis (PCR of 
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epithelial abrasion positive) were analysed. Patients underwent triple-topical therapy 
(polyhexamethilen-biguanide, propamidin-isethionat and neomycin) and with failed 
recovery, subsequent crosslinking, corneal cryotherapy, repeat penetrating keratoplasties, 
amniotic membrane transplantations and phacoemulsification with posterior chamber lens 
implantation. The patients developed ocular hypotony with central vein/artery occlusion 
and retinal/choroidal detachment and had no light perception; therefore, the inflamed eyes 
were enucleated. Histological analysis was performed using haematoxilin-eosin, periodic 
acid- Schiff and Gömöri-methenamine silver staining.  
• For epithelial and endothelial cells a human cell line, and for keratocytes primary cultures 
were used (n=6 each). We used 7.8x10-5-0.02% PHMB or CH, 3.9x10-4-0.1% HD, PD or 
DD, 3.9x10-4-0.0125% PD concentration for 24 hours to determine viability (Cell 
Proliferation Kit XTT), proliferation (Cell Proliferation ELISA BrdU kit) and migration 
using wound healing assay. Viability/proliferation/migration values of each drug were 
summarized as “area under curve” (AUC) together with a Mann-Whitney test. 
• Acanthamoeba castellanii strain 1BU-trophozoites/cysts were challenged with the 
antiamoebic-agents 0.02% PHMB, 0.1% PD and 0.0065% MF. Efficacies of the drugs 
were determined by LDH-release and trypan blue assays. The fluorescent dyes Hoechst 
33343, calcein-AM, and ethidium-homodimer-1 were tested for their abilities to 
differentiate between viable and dead 1BU-trophozoites/cysts following treatment, a 
non-nutrient agar Eshericia coli (E. coli) plate assay was applied to monitor the 
outgrowth of 1BU-trophozoites/cysts challenged with antiamoebic-agents. 
• Acanthamoeba castellanii 1BU strain was cultured in 712 peptone-yeast extract-glucose 
(PYG) medium. Thereafter, trophozoites or cysts were cultured in 0,005-0.02% PHMB, 
CH or 0.25-0.1% HD, PD, DD, or 5% NM or 0.001625-0.0065% MF or 0.25-1% PVPI 
containing PYG medium for 2 hours or underwent Chlorin e6-PDT. Then, the percentage 
of dead trophozoites was determined by CytoTox 96® Non-Radioactive Cytotoxicity 
assay and trypan blue staining and those of cysts using trypan blue staining. Treated cysts 
were also inoculated on non-nutrient agar E. coli plates and were observed for 5 weeks. 
 
Results:  
• We could not observe Acanthamoeba trophozoites or cysts neither in the cornea nor in 
other ocular tissues in the enucleated eyes. There were anterior synechiae in the chamber 
angle of both globes and lymphocytic infiltration around central retinal artery and vein, 
associated with fibrous metaplasia of the retinal pigment epithelium. We saw perivascular 
inflammatory cell infiltration (mainly lymphocytes) in the episclera and around ciliary 
nerves, analysing the first globe. This was associated with non-granulomatous uveitis, 
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cilioschisis and tractional retinal detachment. Cross sections of the optic nerve revealed 
gliosis and optic nerve atrophy. Histopathologic studies of the second globe revealed a 
multifocal, non-granulomatous choroiditis with lymphocytic infiltration. 
• HCEC, keratocyte and HCEC-12 viability AUC, comparing PD and PHMB (p≤0.014 for 
all; PD better) or PD and HD (p≤0.011 for all; PD better) differed significantly. 
Keratocyte and HCEC-12 viability AUC comparing CH and HD (p≤0.027; CH better), 
HCEC-12 viability AUC comparing PD and HD (p=0.005; PD better) and HCEC viability 
AUC comparing CH and PHMB (p=0.014; CH better) differed significantly. HCEC 
proliferation AUC, comparing PD with PHMB, CH, DD, HD (p≤0.016; PD worse for all) 
and keratocyte proliferation AUC, comparing PHMB with HD, PD (p=0.004; p=0.002; 
PHMB better for both), CH with HD, PD (p≤0.001; CH better for both) and DD with PD 
(p=0.043; DD better) differed significantly. Keratocyte migration AUC comparing PD 
with control, PHMB, CH, DD and HD differed significantly (p≤0.012; PD worse for all). 
• All three antiamoebic-agents induced a significant LDH-release from trophozoites, when 
compared to controls (p<0.0001). There was a negligible fluorescent-dye staining in 
untreated 1BU-throphozoites/cysts, but after challenging with antiamoebic-agents, there 
was 59.3-100% trypan blue, 100% Hoechst 33342, 0-75.3% calcein-AM and 100% 
ethidium-homodimer-1 positivity. On non-nutrient agar E. coli plates, in controls and MF 
treated 1BU trophozoites/cysts, new trophozoites appeared within 24 hours, and 
encystment occured after 5 weeks. In PHMB and PD treated 1BU-throphozoites/cysts, 
irregularly shaped, smaller trophozoites appeared after 72 hours, which failed to form 
new cysts within 5 weeks. 
• All concentrations of different antiamoebic agents had a significant cytotoxic effect on 
AK trophozoites and cysts (p<0.05), except 0.02% PHMB or CH, for trophozoites, and 
0.005% CH or Ce6-PDT for cysts, using trypan blue assay. On agar plates, normal shaped 
trophozoites could not be observed using PHMB, CH, HD, PD, NM and PVPI treatment 
and cysts could not be formed again within 5 weeks. DD and MF treated cysts could 
excyst and after one week encyst again. 
 
Conclusions:  
⚫ In long-standing, recalcitrant Acanthamoeba keratitis, uveititis, retinal vasculitis and 
scleritis may occur and result in blindness, even without further persistence of 
Acanthamoeba trophozoites or cysts. In this stage of Acanthamoeba keratitis, systemic 
immune suppression may be necessary for a longer time period. 
⚫ Chlorhexidin as biguanide and propamidin-isethionate as diamidine may be used clinically 
to reduce cytotoxicity of antiamoebic treatment on human corneal cells. Diamidines 
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reduce proliferation of human epithelial cells and keratocytes more than biguanides and 
propamidin-isethionate reduces migration of keratocytes. Therefore, in spite of lower 
cytotoxicity, the inhibitory effect on proliferation and migration indicates that extended 
use of propamidin-isethionate should be avoided in patients. 
⚫ None of the enzymatic- and dye-based viability assays tested here generated survival 
rates for trophozoites/cysts that were comparable with those yielded with the 
non-nutrient agar E. coli plate assay, suggesting that the culture-based assay is the best 
method to study the treatment efficacy of drugs against Acanthamoeba. 
⚫ PHMB, CH, HD, PD, NM and PVPI seem to be more effective against Acanthamoeba 
castellani 1BU strain, than DD and MF. In vitro analysis of treatment efficacy of 
different antiamoebic agents, especially the non-nutrient agar Eschericia coli plate assay 
may provide information on specific treatment of different Acanthamoeba strains in the 
future. 
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ZUSAMMENFASSUNG 
Wirkung von Anti-Amöbika auf humane korneale Zellen und den 
Akanthamöben castellanii 1BU-Stamm 
 
Hintergrund: Die Akanthamöben-Keratitis (AK) ist eine progressive, potentiell 
blindmachende Erkrankung. Die richtige Diagnose wird bei den Patienten oft erst verzögert 
gestellt. In einem frühen Stadium beobachten Augenärzte pseudodendritiforme 
Epitheliopathie, "schmutziges Epithel", punktförmige multifokale stromale Infiltrate und eine 
radiale Perineuritis. Später entwickelt sich ein Ringinfiltrat und bei langjähriger, hartnäckiger 
Akanthamöben-Keratitis, kann es zur Uveitis, retinale Vaskulitis und Skleritis und sogar zur 
Erblindung kommen. Da AK in der Regel mit einem heterogenem klinischen 
Erscheinungsbild und geringer Inzidenz auftritt, gab es keine klinischen Studien, die 
verschiedene Behandlungsmodalitäten bei dieser Krankheit verglichen hätten. Es wurde daher 
noch keine standardisierte Behandlung der AK etabliert. Das Fehlen einer standardisierten 
Therapie gegen die AK ist auch zum Teil auf das Fehlen einer allgemeinen Richtlinie zur 
Therapie einer Akanthamöben Infektion zurückzuführen. 
 
Ausgehend davon hatten wir folgende Ziele für diese Arbeit: 
- Histologische Analyse von zwei Akanthamöben-Keratitis-Augen mit Entzündungen 
im vorderen und hinteren Segment und Erblindung. 
- Es sollte die Wirkung von Biguaniden (Polyhexamethylenbiguanid (PHMB), 
Chlorhexidin (CH)) und Diamidinen (Hexamidin-Diisethionat (HD), 
Propamidin-Isethionat (PD), Dibromopropamidin-Diisethionat (DD)) auf die 
Viabilität, Proliferation und Migration von humanen kornealen Epithelzellen, 
Keratozyten und Endothelzellen in vitro analysiert werden. 
- Der Vergleich von LDH-Freisetzungstests, Trypanblau- und Fluoreszenzfärbungen 
und nährstofffreien-Escherichia coli (E. coli)-Platten-Tests zur Bestimmung der 
Effektivität von Anti-Amöbika gegen Akanthamöben castellanii Trophozoiten und 
Zysten in vitro. 
- Es sollte die konzentrationsabhängige Wirkung von Biguaniden (PHMB, CH), 
Diamidinen (HD, PD, DD), NM, MF, PVPI und Chlorin e6 Photodynamische 
Therapie (PDT) bei Akanthamöben castellani Trophozoiten und Zysten in vitro 
analysiert werden. 
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Methoden: 
- Zwei Augen von 2 Patienten (Alter 45 und 51 Jahren) mit Akanthamöben-Keratitis 
(Diagnose erfolgte durch PCR des epithelialen Abrasions positiv) wurden analysiert. 
Die Patienten wurden einer dreifach topischen Therapie (Polyhexamethilen-biguanid, 
Propamidin-Isethionat und Neomycin) und aufgrund fehlenden Therapieerfolges mit 
anschließendem Crosslinking, Hornhaut-Kryotherapie, wiederholten perforierenden 
Keratoplastiken, Amnionmembrantransplantationen und Phakoemulsifikation mit 
Kunstlinsenimplantation der hinteren Kammer unterzogen. Die Patienten 
entwickelten eine okuläre Hypotonie mit zentraler Venen/Arterien-Verschluss- und 
Netzhaut-Aderhautablösung und hatten keine Lichtwahrnehmung; daher wurden die 
entzündeten Augen enukleiert. Die histologische Analyse wurde mit 
Hämatoxilin-Eosin, Periodsäure-Schiff und Gömöri-Methenamin-Silberfärbung 
durchgeführt.  
- Für die Zellkulturversuche wurde jeweils eine humane Epithelzell (HCEC)- und 
Endothelzelllinie (HCEC-12) und eine Keratozyten Primärkultur (n=6) verwendet. 
Wir verwendeten 7,8 x 10-5 - 0,02% PHMB oder CH, 3,9 x 10-4 - 0,1% HD, PD oder 
DD, 3,9 x 10-4 - 0,0125% PD-Konzentration für 24 Stunden, um die Viabilität (Cell 
Proliferation Kit XTT), die Proliferation (Cell Proliferation ELISA BrdU Kit) und die 
Migration mittels Wundheilungstest zu bestimmen. Die Ergebnisse der Viabilitäts-, 
Proliferations- und Migrationswerte wurden zusammen mit einem 
Mann-Whitney-Test berechnet und als "area under curve" (AUC) dargestellt. 
- Der Akanthamöben castellanii Stamm 1BU (Trophozoiten und Zysten) wurde mit den 
Antiamöbika 0,02% Polyhexamethylen-biguanid (PHMB), 0,1% 
Propamidin-isethionat (PD) und 0,0065% Miltefosin (MF) inkubiert. Die 
Wirksamkeit der Medikamente wurde durch die LDH-Freisetzung und den 
Trypanblau-Assay bestimmt. Die Fluoreszenzfarbstoffe Hoechst 33343, Calcein-AM 
und Ethidium-Homodimer-1 wurden verwendet, um nach der Behandlung zwischen 
lebensfähigen und toten 1BU-Trophozoiten/Zysten zu unterscheiden. Ein 
nährstofffreier Agar-Eschericia coli (E. coli)-Plattentest wurde angewendet, um das 
Wachstum von 1BU-Trophozoiten und Zysten zu beurteilen, die mit den 
Anti-Acanhtamoeben-Medikamenten behandelt wurden. 
- Die Anzucht des Akanthamöben castellani 1BU Stamm erfolgte in 712 
Pepton-Hefeextrakt-Glukose (PYG) Medium. Anschließend wurden Trophozoiten 
oder Zysten in 0,005-0,02% PHMB, CH oder 0,25-0,1% HD, PD, DD oder 5% NM 
oder 0,001625-0,0065% MF oder 0,25-1% PVPI enthaltendes PYG-Medium für 2 
Stunden inkubiert oder einer Chlorin e6-PDT unterzogen. Anschließend wurde der 
Anteil der toten Trophozoiten durch den CytoTox 96® Non-Radioactive Cytotoxicity 
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Assay  und die Trypanblau-Färbung bestimmt, der Anteil der toten Zysten nur durch 
die Trypanblau-Färbung. Die behandelten Zysten wurden zusätzlich auf nährstofffreie 
Agar E. coli-Platten geimpft und 5 Wochen lang beobachtet. 
 
Ergebnisse:  
- Akanthamöben Trophozoiten oder Zysten konnten wir weder in der Hornhaut noch in 
anderen Augengeweben in den enukleierten Augen beobachten. Es gab anteriore 
Synechien im Kammerwinkel der beiden Augen und lymphozytäre Infiltration um die 
zentrale Netzhautarterie und Vene, verbunden mit fibröser Metaplasie des retinalen 
Pigmentepithels. Wir sahen eine perivaskuläre Infiltration inflammatorischer Zellen 
(hauptsächlich Lymphozyten) in der Episklera und um die Ziliarnerven herum. Die 
Analyse des ersten Auges zeigte eine nicht-granulomatöse Uveitis, Cilioschisis und 
traktive Netzhautablösung. Querschnitte des Sehnervs zeigten eine Gliose und eine 
Sehnervenatrophie. Die histopathologische Untersuchungen des zweiten Auges 
zeigten eine multifokale, nicht-granulomatöse Choroiditis mit lymphozytärer 
Infiltration. 
- AUC der Viabilitätsassays von HCEC, Keratozyten und HCEC-12 unterschied sich 
signifikant im Vergleich von PD gegen PHMB (p≤0.014 für alle; PD besser) und im 
Vergleich von PD und HD (p≤0.011 für alle; PD besser). Die AUC des 
Viabilitätsassay unterschied sich signifikant bei Keratozyten und HCEC-12 im 
Vergleich von CH und HD (p≤0.027; CH besser), bei HCEC-12 im Vergleich von PD 
und HD (p=0.005; PD besser), und bei HCEC im Vergleich von CH und PHMB 
(p=0.014; CH besser). Bei den Proliferationstesten zeigte die AUC bei den HCEC im 
Vergleich von PD gegen PHMB, CH, DD und HD signifikante Unterschiede 
(p≤0.016; PD schlechter für alle). Die Ergebnisse der Proliferationsteste bei den 
Keratozyten zeigten Unterschiede bei der AUC im Verglich von PHMB mit HD und 
PD (p=0.004; p=0.002; PHMB besser für beide), CH mit HD und PD (p≤0.001; CH 
besser für beide), und im Vergleich von DD mit PD (p=0.043; DD besser). Bei den 
Migrationstesten zeigten sich signifikante Unterschiede bei den Keratozyten im 
Vergleich von PD mit der Kontrolle, PHMB, CH DD und HD (p≤0.012; PD 
schlechter für alle). 
- Alle drei Anti-Amöbika induzierten im Vergleich zur Kontrolle eine signifikante 
LDH-Freisetzung bei den Trophozoiten (p<0,0001). Es gab eine vernachlässigbare 
Fluoreszenzfärbung bei unbehandelten 1BU-Throphozoiten/Zysten, aber nach der 
Inkubation mit den Anti-Amöbika zeigten sich in der Trypanblau Färbung 59,3-100%, 
nach der Inkubation mit Hoechst 33342 100%, bei Calcein-AM 0-75,3% und bei 
Ethidium-Homodimer-1 100% positive Zellen. Auf nährstofffreien Agar-E. 
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coli-Platten, traten bei der Kontrolle und den MF-behandelten 
1BU-Trophozoiten/Zysten innerhalb von 24 Stunden neue Trophozoiten auf, nach 5 
Wochen bildeten sich erneut Zysten. Bei den mit PHMB und PD behandelten 
1BU-Throphozoiten/Zysten traten nach 72 Stunden unregelmäßig geformte, kleinere 
Trophozoiten auf, die innerhalb von 5 Wochen keine neuen Zysten bildeten. 
- Bei allen Konzentrationen der verschiedenen amöbenhemmenden Mitteln zeigte sich 
eine signifikante zytotoxische Wirkung auf Akanthamöben Trophozoiten und Zysten 
(p<0,05), mit Ausnahme von 0,02% PHMB oder CH bei Trophozoiten und 0,005% 
CH oder Ce6-PDT bei Zysten unter Verwendung des Trypanblau-Tests. PHMB, CH, 
HD, PD, NM und PVPI Furhten zu morphologischen Veranderungen der  
Akanthamöben-Trophozoiten, die innerhalb von 5 Wochen keine Zysten mehr bilden 
Konnten. Die mit DD und MF behandelten Zysten konnten exzystisch und innerhalb 
von eine Woche wieder enzystisch werden. 
 
Schlussfolgerungen:  
- Bei langjähriger, andauernder Akanthamöben-Keratitis können Uveititis, retinale 
Vaskulitis und Skleritis auftreten und zur Erblindung führen, auch ohne weitere 
Persistenz von Akanthamöben-Trophozoiten oder Zysten. In diesem Stadium der 
Akanthamöben-Keratitis kann eine systemische Immunsuppression über einen 
längeren Zeitraum notwendig sein. 
- Chlorhexidin als Biguanid und Propamidin-Isethionat als Diamidin können klinisch 
eingesetzt werden, um die Zytotoxizität der antiamöbischen Behandlung an humanen 
Hornhautzellen zu reduzieren. Diamidine reduzieren die Proliferation von humanen 
Epithelzellen und Keratozyten mehr als Biguanide. Propamidin-Isethionat senkt die 
Migrationaktivität von Keratozyten. Daher deutet die hemmende Wirkung auf 
Proliferation und Migration trotz geringerer Zytotoxizität darauf hin, dass eine 
längere Verwendung von Propamidin-Isethionat bei Patienten vermieden werden 
sollte. 
- Da die enzymatischen und farbstoffbasierten Vitalitätsteste stark unterschiedliche 
Ergebnisse für Trophozoiten/Zysten aufwiesen, die mit denen des nährstofffreien 
Agar E. coli-Platten-Assays nicht vergleichbar waren, deutet es daraufhin, dass der 
kulturbasierte Assay die beste Methode ist, um die Behandlungseffektivität von 
Medikamenten gegen Akanthamöben zu untersuchen. 
- PHMB, CH, HD, PD, NM und PVPI scheinen effektiver gegen den Akanthamöben 
castellani 1BU Stamm zu sein, als DD und MF. In vitro-Analysen, insbesondere die 
Analyse mit nährstofffreien Agars Eschericia coli Plattenassays können uns 
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Informationen über die Wirksamkeit der verschiedenen amöbenhemmenden Mittel 
bei verschiedenen Akanthamöben-Stämmen liefern.  
 
 




Acanthamoeba species are free-living, ubiquitous protozoa in the nature. They can be isolated 
from soil, air, sea, swimming pool and bottled water. Acanthamoeba can even be isolated 
from nasopharyngeal mucosa of healthy individuals. [Niederkorn H; Siddiqui R 2012]  
It exists in two life forms, active trophozoites and dormant cysts. Cysts are smaller, round, 
double-walled and are highly resistant to a stressful and extreme environment. Acanthamoeba 
cysts may remain dormant but viable for several years or even decades. Encystment occurs 
under stressful conditions such as pH changes or alterations of oxygen or food supply. [Mazur 
T; Aksozek A; Lorenzo-Morales J]  
Trophozoites are the infectious form, resulting in human infection. They result in humans in 
two main types of infection; granulomatous amoebic encephalitis (GAE) - a rare but often 
fatal infection of the central nervous system [Geith S; Doan N], and Acanthamoeba keratitis 
(AK). Infection of the central nervous system predominantly occurs in immunocompromised 
patients and AK in immunocompetent subjects.
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1.2 Acanthamoeba keratitis 
1.2.1 Epidemiology 
Acanthamoeba keratitis (AK) is a relatively rare, but progressive, sight-threatening corneal 
infection, occurring mostly in immunocompetent contact lens wearers. 68%-92.3% of AK 
patients wear contact lenses before development of a keratitis. [Radford CF; Butler TK; Chin 
J; Walochnik J 2015] With increasing use of contact lenses, the number of AK patients is 
likely to increase. [Mathers WD; Panjwani N] 
In Germany, with about 80 million inhabitants, about 150 new AK cases have been reported 
in a 10-year-period [Daas L]. However, AK incidence have been described to increase 
worldwide [Stehr-Green JK; Chomicz L]. In 2002, its annual incidence was 17.53 to 21.14 
per one million contact lens wearers in the UK [Radford CF]. In the US, an AK outbreak was 
associated to a contact lens solution [Verani JR]. Wearing cosmestic contact lenses have also 
shown a higher risk to develop AK [Lee SM].  
 
1.2.2 Pathogenesis 
Expression of mannosilated glycoproteins on corneal epithelial cell surface is upregulated in 
contact lens wearers [Huth S]. This plays an important role in AK pathogenesis. The 
Acanthamoeba throphozoite binds to these proteins though its mannose-binding site in order 
to release the so-called mannose-induced protease 133 (MIP-133) and Acanthamoeba 
plasminogen activator (aPA). MIP-133 and aPA give rise to lysis of epithelial cells, stromal 
cells and stromal matrix, leading to corneal erosions and ulceration [Alizadeh H 2007]. About 
50-100% of the adult population posesses IgG serum antibody against Acanthamoeba 
antigens, however, mice experiments showed that the adaptive immune system cannot 
eradicate Acanthamoeba cysts [McClellan K]. Activation of the adaptive immune system 
through Acanthamoeba increases IL-17A protein expression, which leads to neutrophil 
activation and migration and, therefore, only moderate symptoms of AK, in mice 
[Suryawanshi A].  
Although contact lens wear is considered as a risk of AK development, most interestingly, not 
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each contact lens wearer tends to develop AK, implying that the individual immune response 
may play a crucial role. 
Through mucosal immune system, IgA is produced in human tears, which prohibits 
Acanthamoeba trophozoite binding to the ocular surface. Some contact lens wearers do not 
have this mucosal immune response and, therefore, have higher risk to develop AK [Neelam S; 
Alizadeh H 2001]. This suggests that Acanthamoeba patients may have an immunological 
“blind-spot”, which prevents them from mounting an effective immune response to 
Acanthamoeba antigens.  
In many aspects, the immunology of Acanthamoeba keratitis needs further research to better 
understand its pathogenesis and to find potential intervention points to prohibit its 
development and optimize the human immune response.  
Presence of bacteria or fungi also supports Acanthamoeba growth, therefore, very often a 
co-infection is observed [Gupta N; Nunes TE; Raghavan A]. If the Acanthamoeba cysts reach 
deeper corneal layers, this may account for recurrences and a more severe AK in patients 
[Yokogawa H; AI Kharousi N]. 
 
1.2.3 Clinical signs 
Acanthamoeba keratitis patients suffer at the early stage of the disease from tearing and ocular 
pain. At this time-point, the ophthalmologists observe a relative mild ophthalmological status, 
compared to the pronounced discomfort of the patient. Within the first 2 weeks in 50% of the 
patients there are chameleon-like epithelial changes (“dirty epithelium”). Grey epithelial 
opacities, pseudodendritiformic epitheliopathy, epithelial microerosions or microcyst can be 
observed at this stage (figure 1A). Multifocal stromal infiltrates may also be observed (figure 
1B), which are mostly central or paracentral. In the first month, 20% of the patients develop a 
ring infiltrate (Wessely immune ring) (figure 1C), formed from polymorphonuclear 
leukocytes, antigen-antibody-komplex and complement. Its incidence increases over time. In 
the first month of the disease 2.5-63% of the patients show perineural infiltrates (figure 1D), 
which are radially, from limbus to middle stroma oriented and may result in the long-term in 
neurotrophic keratopathy. Late symptoms (following months) include limbal stem cell 
deficiency (figure 1E), sterile anterior uveitis, scleritis, broad-based anterior synechiae, 
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secondary glaucoma, iris atrophy, mature cataract, chorioretinitis and retinal vasculitis. 
[Szentmáry N 2013; Szentmáry N 2017; Szentmáry N 2018; Daas L]  
 




AK is a serious, sight-threatening disease, in which patients need long-term treatment. 
However, until now, there is no standardized treatment of AK and there is no topical or 
systemic drug which could explicitly eliminate Acanthamoeba trophozoites and especially the 
highly resistant cysts from the human cornea.  
The lack of a standardized therapy against AK is in part due to the lack of a generally agreed. 
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Figure 1. Nonhealing epithelial defect (fluorescein staining) (A), multifocal stromal infiltrates (B), 
ring infiltrate (C), perineuritis (D), limbal stem cell deficiency and nonhealing epithelial defect 
with conjunctivalization of the cornea (E) and stage after curative penetrating keratoplasty (F) in 
AK. Images from the Department of Ophthalmology, Semmelweis University, Budapest, Hungary 
and from the Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, 
Germany. 
 
drug testing regime against Acanthamoeba. Although a number of staining methods and 
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viability tests have been already used to test the efficacy of drugs against Acanthamoeba 
isolates in vitro [Lee X; Siddiqui R 2017; Mito T; Chen Z], a routine method, to enable a 
specific treatment in AK, against the isolated Acanthamoeba, is still not available. 
In addition, since AK presents with heterogeneous clinical appearance and low incidence, 
there have been no clinical trials comparing different treatment modalities in this disease and 
no standardized treatment of AK has been established, yet [Szentmáry N 2013; Szentmáry N 
2017; Szentmáry N 2018]. Therefore, several topical and systemic treatment modalities have 
been used in case series of AK patients. 
Currently, biguanides such as polyhexamethylene biguanide (PHMB) and chlorhexidine (CH), 
diamidines such as hexamidine (HD), propamidin isethionate (PD) and 
dibromopropamidine-diisethionat (DD), are mainly used, as eye-drops (off-label medication) 
[Szentmáry N 2013; Szentmáry N 2017; Szentmáry N 2018; Seal D]. The antibiotic 
neomycin also showed promising antiamoebic effect as topical treatment. Biguanides, 
diamidines and neomycin together are used as a so called triple-topical therapy in 
clinical treatment of AK patients [Szentmáry N 2013; Szentmáry N 2017; Szentmáry 
N 2018; Seal D]. 
Miconazole and clotrimazole have also been previously successfully used as topical treatment 
against AK [D`Aversa G; Amoils SP].  
Natamycin (NM) is known to inhibit fungal growth by binding to sterols and by impairment 
of membrane fusion via perturbation of ergosterol-dependent priming reactions that precede 
membrane fusion [te Welscher YM]. Some studies have shown topical NM successful in 
Acanthamoeba keratitis patients [Jackson TN; Sunada A].  
Miltefosine (MF) is an intracellular targeting agent, which can denature essential cell proteins, 
and disrupt the cell membrane. MF was used successfully in amoebic encephalitis 
[Aichelburg AC] and in several in vitro experiments against Acanthamoeba [Walochnik J 
2009; Mrva M; Polat ZA 2012; Polat ZA 2014].  
PVPI is a broad spectrum microbicide that destroys microbial protein and DNA [Bigliardi PL]. 
1% PVPI can cause ridges of the outer cyst wall and separation of the inner cyst wall from the 
outer one [Sunada A] and seemed to be effective against Acanthamoeba in vitro [Yamasaki K; 
Gatti S].  
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With increasing resistance of microorganisms to antibiotics, photodynamic therapy (PDT) 
may be one potential treatment option [Szentmáry N 2018]. Crosslinking as PDT seems not to 
be effective enough in AK [Hager T; del Buey MA; Makdoumi K]. PDT using Ce6 and red 
light seemed to be effective in treatment of Pseudomonas aeruginosa keratitis [Wu MF; 
Deichelbohrer M], therefore, could also be a potential antiamoebic agent. 
In addition to topical antimycotic treatment, use of systemic voriconazole have also been 
reported in AK patients [D`Aversa G; Amoils SP]. Systemic antiamoebic therapy with oral 
itraconazole (100 mg daily) may probably be a useful adjuvant treatment to prevent 
progression of AK [Schuster FL 2004]. 
In the clinical practice, in addition to high recrudescence, AK patients often present with 
epithelial healing problems [Seal D; Dass L]. The main factors responsible for the cytopathic 
effect and cytolysis of the human cells in AK are the mannose-induced protein MIP-133 and 
the Acanthamoeba plasminogen activator (aPA), secreted through Acanthamoeba trophozoites 
[Niederkorn H]. However, a cytopathic effect through diamidines and biguanides has also 
been described [Johns KJ 1988a; Lee JE; Mafra CSP]. In addition, endothelial 
decompensation occurred following the use of 20% chlorhexidine [Shigeyasu C]. The role of 
diamidines/biguanides and the AK itself in these clinically observed non-healing epithelial 
defects is currently unknown. 
Systemic antiinflammory treatment may additionally also be necessary in advanced cases of 
AK, with limbitis and scleritis, and scleral pain. These symptoms may be managed using oral 
nonsteroidal anti-inflammatory treatment (e.g. flurbiprofen 50 to 100 mg, 2 or 3 times a day), 
in moderate cases. In more severe cases, high-dose systemic steroid therapy (prednisolone 1 
mg/kg/day) followed by systemic cyclosporine (3 to 7.5 mg/kg/day), can be used. Systemic 
immunosuppression is necessary in average for 7 months in such cases [Lee GA].  
 
Surgical treatment 
If conservative treatment is unsuccessful, surgical treatment methods are used to cure AK, or 
to decrease severity of the symptoms.  
Using corneal cryotherapy, the infected corneal areas or the recipient corneal area before 
penetrating keratoplasty will be treated by “freeze-thaw-freeze" cycles 2–3 times in 360° 
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[Klüppel M, 1997]. The exact effect of this treatment method on limbal epithelial stem cells 
has not been clarified, yet. 
An amniotic membrane transplantation (AMT) is often used in case of nonhealing epithelial 
defects, to support epithelial healing. AMT as “Graft” or “Sandwich” may also be applied to 
heal AK-related corneal ulcer and to reach a quiet stage of the eye (figure 1F) [Seitz B 2006].  
In the case of progressive, therapy-resistant ulceration over weeks and months with peripheral 
reparative neovascularization, we suggest an early (<5 months disease course) à chaud 
penetrating keratoplasty [Laurik KL]. The aim is to remove the infected corneal tissue, before 
expansion of AK to the corneoscleral limbus. 
Following penetrating keratoplasty, we generally continue with triple-topical-therapy over 
about a year [Hager T].  
In the case of perforated corneal ulcers, a non-mechanical, excimer laser penetrating 
keratoplasty is advantageous [Küchle M; Seitz B 1999]. Using an elliptical excimer laser 
trephination with metal masks, we may remove the infected corneal area with a more 
homogeneous distance from the limbal vessels, in typically elliptical-shaped AK [Szentmáry 
N 2007].  
Nevertheless, in some cases, removal of the eye though enucleation may also be necessary, 
due to loss of eye function and unbearable pain [Awwad ST; Laurik KL]. 
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1.4 Thesis aims 
In order to get more insight into an optimized clinical treatment of AK, our study purposes 
were as follows: 
⚫ Histological analysis of two Acanthamoeba keratitis eyes with anterior and posterior 
segment inflammation and blindness. 
⚫ To analyze the effect of biguanides (polyhexamethylen biguanid (PHMB), chlorhexidine 
(CH)) and diamidines (hexamidine-diisethionat (HD), propamidin-isethionate (PD), 
dibromopropamidine-diisethionat (DD)) on human corneal epithelial cell, keratocyte and 
endothelial cell viability, proliferation and migration, in vitro. 
⚫ To compare LDH release assay, trypan blue and fluorescent stainings and non-nutrient 
Escherichia coli (E. coli) plate assay in determining treatment efficacy of 
antiamoebic-agents against Acanthamoeba castellanii trophozoites and cysts, in vitro. 
⚫ To analyze the concentration dependent effect of biguanides (PHMB, CH); diamidines 
(HD, PD, DD); natamycin (NM); miltefosine (MF); povidone iodine (PVPI) and chlorin 
e6 photodynamic therapy (PDT) on Acanthamoeba castellanii 1BU trophozoites and cysts , 
in vitro. 
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2 MATERIALS AND METHODS 
2.1 Histological analysis of Acanthamoeba keratitis eye 
globes 
2.1.1 Patient history 
We performed a retrospective record review between January 2006 and December 2017, at 
the Department of Ophthalmology of Saarland University Medical Center, Homburg/Saar 
searching for patients with the diagnosis of Acanthamoeba keratitis (polymerase-chain 
reaction (PCR) positive) and subsequent enucleation. During this time period, there were 30 
PCR positive AK patients and 2 of them underwent enucleation. 
These two patients were both contact lens wearers and their clinical history is described below. 
In these two eyes of 2 female patients (age 45 and 51 years) PCR of epithelial abrasion 
confirmed the clinical diagnosis of Acanthamoeba keratitis (time to diagnosis after first 
symptoms 2 weeks and 3 months). These cases had been treated previously as herpetic or 
herpetic/bacterial keratitis, in another hospital, respectively. There was no evidence of 
previous or subsequent systemic disease in any of the patients. Best corrected visual acuity at 
the time of diagnosis was 0.2 and 0.05 and clinical signs of AK were dirty epithelium and 
multifocal stromal infiltrates (Figure 2A) in the first and corneal ulcer, ring infiltrate, keratic 
precipitates, hypopyon, intrastromal bleeding and posterior synechiae in the second eye 
(Figure 3A).  
The patients underwent triple-topical therapy (polyhexamethilen-biguanide, 
propamidin-isethionat and neomycin) and with failed recovery (2 and 5 months after first AK 
symptoms and with continuous triple-topical therapy), surgical therapies followed. Before 
surgery, during continuous triple therapy there were persisiting epithelial defects in both 
patients, with the size of about 4x5mms and 7x8mms. Repeat iatrogenic epithelial removals 
were not performed. Although persisting epithelial defects may also be related to the toxicity 
of the used triple-therapy itself, we interpreted their presence as lack of success with 
antiamoebic therapy and performed surgery. 
The first patient received crosslinking (CXL) with amniotic membrane transplantation as 
patch, 2 months after first symptoms. All amniotic membranes have been prepared in our eye 
bank and were used following cold storage (-80°C), for both patients. Corneal cryotherapy 
with PKP was performed 3 months (8.0/8.1 mm excimer laser trephination) (Figure 2B) after 
initiation of keratitis. One month later, repeat PKP in combination with phacoemulsification 
and posterior chamber lens implantation and amniotic membrane transplantation as patch has 
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been performed (triple-procedure, 10.0/10.5 mm hand-held trephination, repeat PKP for AK 
recurrence and host calcification, along the interface) (Figures 2C-D). Histological analysis 
of both explanted corneal tissues (PKP and repeat PKP) revealed presence of trophozoites and 
cysts, veryfiing unsuccessfull previous triple-therapy. 
The second patient underwent CXL, subsequent corneal cryotherapy with PKP and amniotic 
membrane transplantation as patch (7.5/7.6 mm excimer laser trephination) 5 months (Figure 
3B-C) after first symptoms. Two months later, she had phacoemulsification with posterior 
chamber lens implantation and repeat PKP (8.0/8.1 mm excimer laser trephination, for 
non-healing epithelial defects). Histological analysis of both explanted corneal tissues (PKP 
and repeat PKP) revealed presence of trophozoites and cysts, also referring to failed previous 
triple-therapy. Thereafter, with non-healing epithelial defects, amniotic membrane 
transplantations as patch were performed 5 times.  
Beside our “standard” systemic immune modulatory treatment after PKPs (250- 150- 150- 
125- 125- 100- 100- 80- 80- 64- 64- 32- 32- 16- 16- 8 -8 mgs methylprednisolon), no 
additional immune suppression had been used after keratoplasties. We took this decision, as at 
this time-point, our patients did not show signs of severe anterior and posterior segment 
inflammation or corneal vascularization. 
Following PKPs, best corrected visual acuity was hand movement and 0.1. Triple-topical 
therapy was continued 5x daily with additional prednisolone-acetate eye drops 5x daily. 
However, the epithelial defects further did not heal and the patients developed secondary 
glaucoma 3 and 6 months after presentation of first AK symptoms, which was successfully 
cured with conservative therapy. This was followed by central artery occlusion (CRAO) in the 
first patient 5 months and with central vein occlusion (CRVO) in the second patient 6 months 
after first AK symptoms. CRAO and CRVO were diagnosed through fundus examination. 
Fluorescein angiography could not give us additional information through the deepithelialized 
and oedematous transplanted corneas. 
The first patient ended up with ciliary body, choroid and retinal detachment 11 months 
after first keratitis symptoms and, therefore, sclerotomy, pars plana vitrectomy with 
silicon oil implantation was performed. The second patient, with subsequent central 
retinal vein occlusion, received intravitreal Bevacizumab 9 and 10 months after first 
AK symptoms.  
Ocular hypotony became obvious in both patients 11 and 9 months, respectively, after 
the first AK symptoms (Figure 2E-F and Figure 3D). A “filamentous, spider-net-like” 
inflammatory reaction was detected in the anterior chamber of the second patient 
simultaneously with ocular hypotony, 9 months after first AK symptoms (Figure 3D). 
Three months after repeat PKP, both patients had no light perception (7 and 12 months 
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after the first symptoms of AK) and subsequently, also due to pain, the inflamed blind 
eyes were enucleated (13 months after the first symptoms of AK in both patients). 
 
 
Figure 2. Images of the first case. Acanthamoeba keratitis with “dirty epithelium” and multifocal 
stromal infiltrates (A), after first PKP (B) and recurrence of AK and calcification in recipient along 
interface (arrows) (C), following repeat PKP with amniotic membrane transplantation as patch (D) 
and with ocular hypotony, retinal and choroidal detachment (E). 
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Figure 3. Images of the second case. Acanthamoeba keratitis with corneal ulcer, ring infiltrate, 
intrastromal bleeding and posterior synechiae (A), after first PKP and amniotic membrane 
transplantation as patch (B), with mature cataract (C) and with “filamentous, spider-net-like” 
inflammatory reaction in the anterior chamber (D). 
 
2.1.2 Histological analysis 
Histological analysis of the enucleated eyes was performed at the Department of Pathology of 
Saarland University, Homburg/Saar, Germany and at the Department of Ophthalmology of the 
Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany. 
After formaline-fixation and paraffin wax-embedding of the patients’ enucleated eyes, 3 μm 
thickness sections were cut using a standard microtome and transferred onto microscope 
slides (SuperFrost, Menzel–Gläser, Braunschweig, Germany). We performed serial sections 
anteroposteriorly (parallel to the optical axis) and cross-sections of the optic nerves. The 
slides were dried at 37 °C overnight. Standard haematoxylin–eosin, periodic acid Schiff 
(PAS1) and Gömöri-methenamine silver (GMS) stainings were then performed. Using PAS1 
and GMS stainings, we analyzed presence/absence of trophozoites or cysts in the enucleated 
eyes. With GMS, we also aimed to determine presence/abcence of a mycotic infection of the 
enucleated eyes. Further on we will name the first patient’s eye globe as „first case”, and the 
second patient’s eye globe as „second case”. 
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2.2 Human corneal cell cuture experiments 
A part of this dissertation (chapters 2.2, 3.2 and 4.2 as much as 
Summary/Zusammenfassung on human cells) have been published in “Shi L, Stachon T, 
Seitz B, Wagenpfeil S, Langenbucher A, Szentmáry N. The effect of antiamoebic agents on 
viability, proliferation and migration of human epithelial cells, keratocytes and endothelial 
cells. Curr Eye Res 2018; 43: 725-33.”. To use data of this publication for this doctoral 
dissertation was approved by Current Eye Research. 
 
2.2.1 Reagents 
The materials used included Culture Medium DMEM/F-12 (Life Technologies, Paisley, UK), 
Dulbecco’s Phosphate Buffered Saline (Sigma-Aldrich, Steinheim, Germany), fetal bovine 
serum (FBS) (Life Technologies, Paisley, UK), penicillin-streptomycin (P/S) (Sigma-Aldrich, 
USA), dimethylsulfoxide (DMSO) (Central Chemical Storage of Saarland University, 
Saarbrücken, Germany), human epidermal growth factor (hEGF) (Biochrom GmbH, Berlin, 
Germany), insulin-transferrin-selenium (Life technologies, Paisley, UK), trypsin-EDTA 
solution (Sigma-Aldrich, USA), cell Proliferation Kit XTT (AppliChem, Darmstadt, 
Germany), cell proliferation ELISA BrdU (colorimetric) kit (Roche, Mannheim, Germany), 
sulfuric acid (Titrisol, Darmstadt, Germany), PHMB (Pharmacy of Saarland Medical 
University, Homburg/Saar, Germany) and CH (Sigma-Aldrich, USA), HD (European 
Pharmacopoeia, Strasbourg, France), DD (European Pharmacopoeia, Strasbourg, France), PD 
(Brolene, Patheon UK Ltd., Swindon, UK). 
 
2.2.2 Cell culture 
a) Human corneal epithelial cell line (HCECs), RCB2280/ HCE-T, SV40-large T (RIKEN 
BioResource Center, Ibaraki, Japan) 
b) Primary normal human keratocyte cultures  
c) Human corneal endothelial cell line (HCEC-12), ACC 646/HCEC-12m, SV40 large 
T-antigen and small t-antigen (RIKEN BioResource Center, Ibaraki, Japan) 
 
For the following experiments, HCECs were cultured using DMEM/F12 culture medium with 
5% FBS, 0.5% DMSO, 1% ITS, 1% P/S, and 10ng/ml hEGF (medium 1). Keratocytes and 
HCEC-12 were cultured using DMEM/F12 culture medium with 5% FBS (medium 2). 
 
2.2.3 Isolation of primary human corneal keratocytes 
Six normal human corneas were obtained from the LIONS Cornea Bank Saar-Lor-Lux, 
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Trier/Westpfalz, Germany. On the basis of endothelial cell density, these corneas did not meet 
the criteria for transplantation. 
To isolate keratocytes, the human corneoscleral buttons were aseptically rinsed in 
phosphate-buffered saline (PBS) before removal of the endothelium including Descemet’s 
membrane using a sterile surgical disposable scalpel. A central corneal button with epithelium 
was cut using a 8.0 mm hand-held trephine and thereafter incubated in culture medium 
containing 2.4 U/mL Dispase II for 4 h at 37 C. Thereafter, the corneal button was washed 
several times with PBS and the already loose corneal epithelium removed. The remaining 
corneal stroma was incubated in culture medium with 1.0 mg/mL collagenase A for 8–10 h at 
37°C. The digested tissue and cells were pipetted three times and centrifuged at 800g for 7 
minutes and finally resuspended in 1.0 mL culture medium, which consisted of basic medium 
(DMEM/F12) supplemented with 5% FCS and 1% P/S. The cell suspension was seeded in 
6-well plates and the medium was changed 24 hours after seeding. The medium was changed 
every 2 to 3 days until keratocytes reached confluence. The cells were subcultured in 25 cm2 
culture flasks after 5 to 10 days following dispersal with 0.05% trypsin-EDTA for 3 to 5 min, 
and the passage four to eight of cells was used for experiments. 
 
2.2.4 Drug preparation 
We received HD, DD and CH in powder form, PHMB as 20% solution. Propamidine 
isethionate was available in 0.1% Brolene® eye drop form. Drugs were dissolved in different 
culture media, depending on cell type: for HCECs medium 1 and for HCEC-12 and 
keratocytes medium 2 was used.  
The maximal concentrations used were 0.02% (w/v) for PHMB and CH, and 0.1% 
(weight/value (w/v)) for HD and DD (clinically used concentrations). The maximal 
concentration for PD was 0.0125% (w/v) (1/8 of 0.1% Brolene® eye drop concentration, as 
the eye drops had to be diluted with culture medium). Thereafter, all solutions underwent a 
serial two fold-dilution. The concentration gradients used were 1/256, 1/128, 1/64, 1/32, 1/16, 
1/8, 1/4, 1/2 of the initial maximal concentration. Cell cultures without diamidine and 
biguanide were used as controls. 
 
2.2.5 Determination of viability 
Viability was determined using the Cell Proliferation Kit XTT. This measurement involves the 
activity of mitochondria in the living cells, causing reduction of the tetrazolium salt XTT to 
orange-colored compounds of formazan. The test was performed according to the 
manufacturer’s protocol. 
All cell types were seeded in 96-well plates. HCECs were seeded at 2.8 x104 HCECs/cm2 
(100µl/well) (n=6), keratocytes at 2.8 x104 keratocytes/cm2 (100µl/well) (n=6) and HCEC-12 
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at 3.3x104 HCEC-12/cm2 (100µl/well) (n=6). Thereafter, all cell types were cultured for 24 
hours until reaching 90% confluence. Once this stage was reached, the culture medium was 
replaced by drug containing media, using 9 different concentrations from 7.8x10-5% to 0.02% 
(from 1/256 to maximal concentration) for PHMB and CH and from 3.9x10-4% to 0.1% (from 
1/256 to maximal concentration) for HD or DD, from 3.9x10-4% to 0.0125% (from 1/256 to 
1/8 concentration) for PD (in a sequence of two fold-diluted concentrations, starting from the 
highest concentration). Cell cultures without drugs were used as controls. 
After culturing the cells for another 24 h, 50 µl/well XTT-containing reaction solution was 
added and all cell types (with different concentrations) were incubated at 37°C for 2 h. 
Following this incubation period, the measurement was performed immediately using a 
96-well microplate reader (Tecan Infinite Reader, TECAN Deutschland GmbH, Crailsheim, 
Germany) at 450 nm wavelength (reference wavelength: 690 nm). 
 
2.2.6 Determination of proliferation 
Cell proliferation was determined using the cell proliferation ELISA BrdU (colorimetric) kit, 
according to the manufacturer’s protocol. In this assay, BrdU is incorporated instead of 
thymidine into the DNA of proliferating cells.  
All cell types were seeded again in 96-well plates. HCECs were seeded at 2.0 x104 
HCECs/cm2 (100µl/well) (n=6), keratocytes at 2.0 x104 keratocytes/cm2 (100µl/well (n=6) 
and HCEC-12 at 2.5 x104 HCEC-12/cm2 (100µl/well) (n=6). Cells were cultured for 24 hours 
until reaching 70% confluence. Thereafter, the culture medium was replaced by drug 
containing media, using 3 different concentrations for all drugs: from 7.8x10-5% to 3.1x10-4% 
(from 1/256 to maximal concentration) for PHMB and CH (in between a series of two 
fold-diluted concentrations, starting from the highest concentration), and from 3.9x10-4% to 
1.6 x10-3% (from 1/256 to maximal concentration) for HD, PD and DD. Cell cultures without 
drugs were used as controls. 
After culturing the cells in drug containing medium for another 24 h, 10µl/well BrdU labeling 
solution was added to the cultures and cells were incubated at 37°C for 2 h (BrdU 
incorporation). After removal of the drug containing medium, cells were fixed with FixDenat 
solution (provided with the test kit), followed by incubation with an anti-BrdU-POD 
(monoclonal antibody to the thymidine-analogue 5-bromo-2‘-deoxyuridine Fab fragments 
conjugated with peroxidase) (100µl/well) for 90 min. This agent binds the incorporated DNA. 
Following removal of the solution, all 96-well plates were rinsed with 200µl/well washing 
buffer three times. Thereafter, 100µl/well tetramethyl-benzidine substrate solution was added, 
and then 50µl/well 1-N-sulfuric acid was added to stop the reaction after color development 
was sufficient for photometric detection (10-30 min). Plates were analyzed using a 96-well 
microplate reader (Tecan Infinite Reader, TECAN Deutschland GmbH, Crailsheim, Germany) 
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at 450 nm wavelength (reference wavelength: 690nm). 
 
2.2.7 Wound healing assay 
Cell migration was determined by the wound healing assay. For this assay, all cell types were 
seeded in 12-well plates again. HCECs were seeded at 3.8 x104 HCECs/cm2 (n=6), 
keratocytes at 3.5 x104 keratocytes/cm2 (n=6) and HCEC-12 at 4.5 x104 HCEC-12/cm2 (n=6). 
Cells were cultured for 24 hours until reaching confluence. Thereafter, cell monolayers were 
scratched by 200µl yellow pipette tips (Eppendorf AG, Hamburg, Germany). Subsequently, 
culture medium was removed and cells were rinsed twice with PBS. Thereafter, for HCECs 
and for HCEC-12, a culture medium with the lowest drug concentration for all drug groups 
was added (3.9x10-4 % (1/256 of maximal concentration) for HD, PD and DD and 7.8x10-5 % 
(1/256 of maximal concentration) for PHMB and CH. For keratocytes, the concentrations 
used were 1.6x10-4 % (1/128 of maximal concentration) for PHMB and CH, and 7.8x10-4 % 
(1/128 of maximal concentration) for HD, PD and DD, due to the morphological and 
migration speed difference of these cells. Cell cultures without drugs were used as controls.  
Images were taken from the original scratch gap and after 6 h, 9 h, 12 h and 24 h of 
incubation. For each well, two images were taken from different parts of the gap and the mean 
of these two measurements was used for the subsequent statistical analysis. The area of the 
scratch gap (for each image, and for each time-point) was measured using the Image J 
Program MRI-wound-healing-tool (National Institute of Health, USA).  
 
2.2.8 Statistical analysis 
Statistical analysis was performed using SPSS 20.0 (IBM, Armonk, NY: IBM Corp, USA).  
A Kruskal-Wallis test was performed to check for the overall effect of drugs on human 
corneal cell viability, proliferation and migration (separate for HCEC, keratocytes and 
HCEC-12).  
To test for the overall efficacy of the drugs, viability, proliferation and migration values for 
each drug and for each sample (cornea 1 to 6) were summarized for all concentrations as a 
measure of area under the curve (AUC) (separate for HCEC, keratocytes and HCEC-12).  
If the Kruskal-Wallis test indicated an effect of the drug on human corneal cell viability, 
proliferation and migration, a non-parametric Mann-Whitney U-test was used to compare 
viability, proliferation and migration AUC values between pairs of drugs (separate for HCEC, 
keratocytes and HCEC-12). Bonferroni correction was performed for multiple testing. P 
values ＜0.05 were considered statistically significant. 
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2.3 Comparison of assays to study the effectiveness of 
antiparasitics against Acanthamoeba castellanii trophozoites 
and cysts 
2.3.1 Medium and non-nutrient agar preparation 
Peptone-yeast-glucose (PYG) medium: 20 g of proteose-peptone (Sigma-Aldrich, St. Louis, 
USA), 1 g of yeast extract (Sigma-Aldrich), 8 ml of a 0.05M CaCl2 (Gruessing GmbH, Filsum, 
Germany) solution, 10 ml of 0.4 M MgSO4×7H2O (Gruessing GmbH) solution, 10 ml of 0.25 
M Na2HPO4×7H2O (Sigma-Aldrich), 10 ml of 0.25M KH2PO4 (Gruessing GmbH) solution, 1 
g of Na Citrate×2H2O (Gruessing GmbH), and 10 ml of 0.005 M Fe(NH4)2(SO4)2×6H2O (Carl 
Roth GmbH, Karlsruhe, Germany) solution were added to 0.95 L distilled water. The pH of 
the medium was adjusted to 6.5, and the solution was subsequently autoclaved at 121°C for 
15 min. 18 g glucose (Sigma-Aldrich) was added to 50 ml distilled water. Thereafter it was 
filter sterilized and added to the above solution. 
Neff’s constant-pH encystment medium: 7.46 g of KCL (Gruessing GmbH), 1.97 g of 
MgSO4*7H2O (Gruessing GmbH), 44.40 mg of CaCL2*2H2O (Gruessing GmbH), 84.01 mg 
of NaHCO3 (Gruessing GmbH), and 2.42 g of Tris-HCL (Gruessing GmbH) were dissolved in 
1 L distilled water. The pH of the solution was adjusted to 9.0, and the medium autoclaved at 
121°C for 15 minutes. As these cooled to room temperature, solution A and B were mixed. 
Page’s amoeba saline (PAS): 0.14 g of Na2HPO4 (Sigma-Aldrich) and 0.14 g of KH2PO4 
(Sigma-Aldrich) were dissolved in 500 ml of distilled water as soltion A, 0.12 g of NaCl 
(Gruessing GmbH), 4 mg of MgSO4×7H2O (Gruessing GmbH) and 4 mg of CaCL2*2H2O 
(Gruessing GmbH) were dissolved in 500 ml of distilled water as solution B, then both 
solutuions were autoclaved at 121°C for 15 minutes. Following reaching room temperature, 
solutions A and B were mixed.  
Non-nutrient agar: 15 g of agar (Sigma-Aldrich) was mixed with 100 ml PAS and 900 m1 
distilled water, then was autoclaved at 121°C for 15 minutes. 
 
2.3.2 Acanthamoeba isolate 
The Acanthamoeba castellanii strain 1BU which was isolated from an AK patient, was 
received from the Unit for Mycotic, Parasitic and Mycobacterial Infections (FG16) of the 
Robert Koch Institute, Berlin, Germany. 
 
2.3.3 Acanthamoeba cultures 
1BU trophozoites were grown in tissue culture flasks containing 5 ml of PYG broth medium 
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at 30°C, in an airtight container. Encystment was induced by adding Neff’s constant-pH 
encystment medium to trophozoites, instead of PYG broth medium, after trophozoites had 
reached confluence.  
Following incubation of the 1BU trophozoites in Neff`s constant-pH encystment medium for 
1 week at 30°C, cysts were harvested through 3-times repeated washing (PBS, Sigma-Aldrich) 
and centrifugation (800 x g) steps, then were resuspended in 5ml PAS with a concentration of 
3.30 x 106 cysts/ml and were stored at 4°C until usage. 
 
2.3.4 Antiamoebic agents and their preparation 
We used as antiamoebic agents polyhexamethylen biguanid (PHMB, Pharmacy of Saarland 
Medical University, Homburg/Saar, Germany), propamidin isethionate (PD, Brolene, Patheon 
UK Ltd., Swindon, UK) and miltefosine (MF, Sigma-Aldrich).  
PHMB was received as a 20% solution, PD as 0.1% Brolene® eye drops, and MF in powder 
form. These agents were dissolved or diluted in PYG medium for treatment of 1BU 
trophozoites, and in PBS for treatment of 1BU cysts (final concentrations were 0.1% PHMB, 
0.02% PD and 0.0065% MF). The above concentrations were set analog  the clinically used 
concentrations in human AK treatment (eye drops) (Table 1). As controls, 1BU trophozoites 
were cultivated in PYG medium and 1BU cysts in PBS 
 
Table 1. Antiamoebic agent concentrations in experiments to test Acanthamoeba viability. 
Agents Concentrations 
PHMB 1079 µM 
(0.02% ) 
 
PD 1771 µM 
(0.1% ) 
MF 160 µM 
(0.0065%） 
 
2.3.5 LDH release assay (cytotoxicity) 
Lactate dehydrogenase (LDH) activity in the supernatants of untreated and drug-challenged 
Acanthamoeba was determined with the CytoTox 96® Non-Radioactive kit (Promega 
Corporation, Madison, USA). For the determination of the cytotoxic effects of antiamoebic 
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drugs on A. castellanii trophozoites, 1x104 1BU trophozoites were incubated in 96-well plates 
with 100 µl PYG medium/well at 30°C for 24 hours. During this time, 1BU trophozoites 
attached to the plate bottom and reached confluence. After 24 hours, PYG medium was 
replaced by 100 µl of the antiameobic agent-containing medium (preparation described above) 
and the throphozoites were incubated for 2 hours at 30°C.  
To determine the cytotoxic effect of antiamoebic drugs on A. castellanii cysts, 2 x 104 1BU 
cysts were incubated in 96-well plates with 100 µl antiamoebic agent containing medium at 
30°C for 2 hours. Negative controls received at the same time point 100 µl fresh PYG 
medium, and positive controls were incubated with 100 µl fresh PYG, supplemented with 10 
µl lysis solution (provided by the kit). Controls were also incubated at 30°C for 2 hours. 
Thereafter, 96-well plates were centrifuged at 200 x g (trophozoites) and 400 x g (cysts) for 5 
minutes, respectively, and 50 µl of the supernatants were removed from each well and 
transferred into the wells of a fresh 96-well plate. 50 µl of substrate reagent was added to each 
well, the solution was carefully mixed and was incubated for 30 minutes at room temperature. 
The reaction was stopped by adding 50 µl stop solution to each well. The LDH catalyzed 
formazan formation was determined spectroscopically with a multimode microplate reader 
(PerkinElmer EnsightTM, USA) at 490 nm, that was blanked with medium and antiamoebic 
agent containing medium, respectively.  
Cytotoxicity (%) was determined as follows: 
Cytotoxicity (%) = 100 × (Experimental LDH Release OD490-Blank control OD490) / 
(Maximum LDH Release OD490 -Blank control OD490) 
 
2.3.6 Trypan blue assay 
2 x 104 1BU trophozoites or cysts were suspended in 100 µl of PYG or antiamoebic agent 
containing medium (preparation described above for each agent) in 1.5 ml reaction tubes 
(Sarstedt, Nümbrecht, Germany) and incubated in a Thermomixer (Eppendorf AG, Hamburg, 
Germany) with a shaking rate of 650 rpm at 30°C for 2 hours. Thereafter, all reaction tubes 
were centrifuged at 200 g for 5 minutes and 80 µl supernatant was removed from each tube. 
As a next step, 20 µl of a 0.4% trypan blue solution (Sigma-Aldrich) was added to each tube 
and throphozoites or cysts were incubated at room temperature for 5 minutes. 1BU 
trophozoites and cysts without trypan blue staining served as negative controls. Thereafter, 10 
µl of the trypan blue treated cells was pipetted to a hemocytometer (C-Chip, NanoEnTek, 
Waltham, USA) and bright field images were taken with a Leica DMI4000 B microscope 
(Leica Microsystems, Wetzlar, Germany) at 10-fold magnification, using Leica Application 
Software (LAS) v3.7.  
Using Image J (National Institute of Health, USA), we analyzed grey value for each blue 
stained cell. Unstained cells in control group and other treated groups were not included. Then, 
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we calculated the mean grey value for all blue stained cells in each group separately and 
defined the grey value for each blue-stained cell, compared to the mean value as percentage. 
With this method, we summarized the cell amount in grey value ranges 85%-90%, 
90%-95%, >95%. 
 
2.3.7 Fluorescent staining 
1BU trophozoites or cysts (2 x 104 cells/well) were resuspended in 100 µl PYG (trophozoites) 
or PBS (cysts) in absence or presence of the antiamoebic agents, and were pipetted into a 
96-well plate, which was subsequently incubated for 2 hours at 30°C. As a positive control, 
primary human corneal keratocytes (104 cells/well) were resuspended in DMEM/F-12 
medium (Thermofisher, Paisley, UK), pipetted into 96-well plates, and were incubated for 2 
hours at 37°C.  
1BU containing 96-well plates were subsequently centrifuged at 200 x g (trophozoites) or 400 
x g (cysts) for 5 minutes, to remove the antiamoebic agent containing media. 
As a next step, cells were resuspended in 100 µl of fluorescent stain solution (Hoechst 33342 
[10 µg/ml] or a mixture of calcein-AM [4 µM] and ethidium homodimer-1 [1 µM]) and were 
incubated in the well plates for 30 minutes at room temperature in the dark. Thereafter, wells 
were washed 3-times with PBS to remove unbound fluorescent dyes, and cells were 
resuspended in PBS.  
Cell images were taken with an inverted fluorescence microscope (Leica Microsystems) using 
the following settings: Hoechst 33342 fluorescence was excited at 340 nm and the light 
emission was determined at 510 nm, calcein-AM was excited at 490 nm and light emission 
was determined at 515 nm, and ethidium homodimer-1 was excited at 493 nm and light 
emission was determined at 617 nm.  
Hoechst 33343 stains nuclei of dead and viable cells to blue colour, calcein-AM stains 
cytoplasm of viable cells to green color and ethidium homodimer-1 stains nuclei of dead cells 
to red color. 
 
2.3.8 Non-nutrient agar Escherichia coli plate assay 
The non-nutrient agar Escherichia coli plate assay was carried out essentially as described by 
Narasimhan [Narasimhan S] and Kowalski [Kowalski RP]. First, E. coli strain IM08B [Monk 
IR] was grown overnight on sheep blood agar plates (Becton Dickinson, Heidelberg, 
Germany) at 35°C. Fresh grown IM08B colonies were picked with a cotton swab and 
suspended in PAS, equivalent to a McFarland of 4. 50 µl of this suspension was pipetted onto 
the surfaces of non-nutrient agar plates, and spread out using an L-shaped spreader.  
In a second step, 2 x104 trophozoites or cysts were mixed with 100 µl medium (PYG for 
trophozoites and PBS for cysts) in absence and presence of the antiamoebic agents, and were 
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incubated at 30°C for 2 hours in a Thermomixer (Eppendorf AG) with a shaking rate of 650 
rpm. 10 µl of the cell suspensions was transferred into fresh tubes, mixed with 10 µl of a 
trypan blue solution (0.4%) and was incubated for 5 minutes at room temperature. 980 µl PBS 
was subsequently added to each tube (the drugs were diluted 100 folds) and the cells were 
carefully suspended by pipetting gently up and down. 50 µl of the stained cell suspensions 
(100 cells) were next pipetted into the middle of the non-nutrient agar E. coli plates, and the 
suspension desiccated for around 10 minutes. Next, circles were drawn on the bottom of the 
plates to confine the borders of the Acanthamoeba cell solution, and bright field images of 
these regions were taken. A. castellanii inoculated plates were incubated upside up for 24 
hours at 30°C. Thereafter, plates were sealed by parafilm (Pechiney, Menasha, USA) and 
were incubated upside down for up to 5 weeks at 30°C.  
Bright field images were taken with a Leica DMI4000 B microscope every 24 hours until 72 
hours, then every week until the end of the 5th week, using a 10-fold magnification. These 
experiments were repeated three times on different days. 
 
2.3.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7.02. Results of the LDH release 
(cytotoxicity) and trypan blue assays were statistically analyzed using one-way ANOVA 
followed by Turkey’s multiple comparisons test (to compare the effect of each antiamoebic 
agent).
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2.4 Efficacy of antiamoebic agents and Ce6-PDT against 
Acanthamoeba castellanii 1-BU  
2.4.1 Medium and non-nutrient agar preparation 
PYG medium, Neff’s constant-pH encystment medium, Page’s amoeba saline (PAS) and 
Non-nutrient agar preparation was performed as described at capter 2.3.1  
 
2.4.2 Acanthamoeba isolate 
For these experiments, the same Acanthamoeba castellanii 1BU strain has been used, as 
described under chapter 2.3.2  
 
2.4.3 Acanthamoeba cultures 
Culturing conditions of Acanthamoeba castellanii 1BU strain were also equivalent to the ones 
described under chapter 2.3.3 
 
2.4.4 Antiamoebic agents and their preparation 
For the experiments, the antiameobic agents polyhexamethylen biguanid (PHMB, Pharmacy 
of Saarland Medical University, Homburg/Saar, Germany), chlorhexidine (CH, 
Sigma-Aldrich, USA), dibromopropamidine diisethionat (DD, European Pharmacopoeia, 
Strasbourg, France), hexamidine diisethionat （HD, European Pharmacopoeia, Strasbourg, 
France), propamidin isethionate (PD, Brolene, Patheon UK Ltd., Swindon, UK), natamycin (5% 
natamycin ophthalmic suspension, Alocon laboratories, Fort Worth, USA), povidon-iod (PVPI, 
B. Braun, Melsungen, Germany), miltefosine (MF, Sigma-Aldrich, Switzerland) and Chlorin 
e6 (Ce6, ORPEGEN Pharma, Heidelberg, Germany) were used. 
We received HD, DD, CH, MF and Ce6 in powder form, PHMB as 20% solution and PVPI as 
7.5% solution. Propamidine isethionate was available in 0.1% Brolene® eye drops, natamycin 
in 5% Natamet® eye drop form. These agents were dissolved or diluted in PYG medium for 
treatment of 1BU trophozoites and in PBS for treatment of 1BU cysts (final concentrations 
were the clinically used concentrations and ½ and ¼ of the clinically used concentrations) 
(Table. 2) Trophozoites cultured with PYG medium and cysts cultured with PBS were set as 
controls. 
 
Table 2. Antiamoebic agent concentrations to test antiamoebic agent efficacy against 
Acanthamoeba castellanii 1BU strain. In LDH and trypan blue assays the below 3 different 
concentrations were used. However, for non-nutrient E.coli agar plate assay, the maximum 
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concentration alone used. 
agents maximum Half of maximum Quarter of maximum 
PHMB 
0.02%  (1079µM) 0.01% (539.5µM) 0.005% (269.75µM) 
CH 
0.02% (396µM) 0.01% (198µM) 0.005% (99µM) 
HD 
0.1% (1648µM) 0.05% (824µM) 0.025% (412µM) 
PD 
0.1% (1771µM) 0.05% (885.5µM) 0.025% (442.75µM) 
DD 
0.1% (1384µM) 0.05% (692µM) 0.025% (346µM) 
NM 
5% (75106µM) 2.5% (37553µM) 1.25%  (18776.5µM) 
MF 
0.0065% (160µM)  0.00325% (80µM)  0.001625% (40µM)  
PVPI 
1% (27401µM) 0.5% (13700.5µM) 0.25% (6850.25µM) 
Ce6 
0.0152% (256µM)  0.0076% (128µM)  0.0038% (64µM)  
 
2.4.5 Photodynamic therapy (PDT) using Chlorin e6 (Ce6), trophozoites and cysts 
We received Chlorin e6 stock solution (ORPEGEN Pharma, Heidelberg, Germany) in PBS 
(30mM). For the experiments, fresh Ce6 with 64μM, 128μM and 256μM concentrations was 
prepared, using PYG medium or PBS.  
1 x104 trophozoites were seeded in 96-well plates and were allowed to grow for 24 hours with 
100µl PYG medium before photodynamic treatment. After 24 hours, trophozoites attached to 
plate bottom and reached confluence. Then, we replaced PYG medium by the above 3 
different Ce6 containing PYG medium and incubated the cultures at 37 °C for 60 minutes in 
the dark. As a negative control, a culture with fresh PYG medium was used. Thereafter, 
cultures were washed by 100 µl PBS 3 times to remove the Ce6 containig PYG medium and 
100 µl fresh PYG medium was added.  
2 x104 cysts were seeded in 96-well plates. Thereafter, the above 3 different Ce6 containing 
PBS medium were added and we incubated the cultures at 37 °C for 60 minutes in the dark. 
As a negative control, a culture with PBS was used. Thereafter, the plate was centrifuged at 
400 x g for 5 minutes and was washed by 100 µl PBS 3 times to remove the Ce6 containig 
PBS and 100 µl fresh PBS was added.  
Then, we exposed the cultures (trophozoites or cysts) to red (670 nm) light for 13 minutes (24 
J/cm2). As a negative control without illumination, we kept the culture after removal of the 
Ce6 containing PYG or PBS medium in dark for the illumiation time of the other cultures. 
The used illumination box was developed previously through the Department of Physics of 
the University of Kaiserslautern (Kaiserslautern, Germany) [Wang J; Wu MF; Winkler K].  
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2.4.6 LDH release assay (cytotoxicity), trophozoites 
To determinate the cytotoxic effect of antiamoebic drugs on A. castellanii trophozoites, 1x104 
1BU trophozoites were incubated in 96-well plates with 100 µl PYG medium/well at 30°C for 
24 hours. During this time 1BU trophozoites attached to the plate bottom and reached 
confluence. After 24 hours, PYG medium was replaced by 100 µl of the antiameobic 
agent-containing medium (preparation described above) and the throphozoites were incubated 
for 2 hours at 30°C. Negative controls received at the same time point 100 µl fresh PYG 
medium, and positive controls were incubated with 100 µl fresh PYG supplemented with 10 
µl lysis solution (provided by the kit). Blank controls were incubated with medium or 
antiamoebic agent-containing medium, but without trophozoites. All controls were also 
incubated at 30°C for 2 hours. As lysis buffer in this kit could not lyse cysts, these were not 
analysed using this assay [Shi L, 2019 in press]. 
Thereafter, 96-well plates were centrifuged at 200 x g for 5 minutes, then 50 µl of the 
supernatant was removed from each well and was transferred into wells of a fresh 96-well 
plate. 50 µl of substrate reagent was added to each well, the solution was carefully mixed and 
was incubated for 30 minutes at room temperature. The reaction was stopped by adding 50 µl 
stop solution to each well. The LDH catalyzed formazan formation was determined 
spectroscopically with a multimode microplate reader (PerkinElmer EnsightTM, USA) at 490 
nm, that was blanked with medium and antiamoebic agent containing medium, respectively. 
Cytotoxicity (%) was determined as follows: 
Cytotoxicity (%) = 100 × (Experimental LDH Release OD490 - Blank control OD490) 
/(Maximum LDH Release OD490 - Blank control OD490) 
These experiments were repeated 5 times on different days. 
As the dark brown color of PVPI was similar to the color of the reaction, the effect of PVPI 
on A. castellanii could not be tested using this assay. 
 
 
2.4.7 Trypan blue assay, trophozoites and cysts 
Trypan blue assay was performed as we described previously under chapter 2.3.6 
 
2.4.8 Non-nutrient agar Escherichia coli plate assay, cysts 
The non-nutrient agar Escherichia coli plate assay was carried out essentially as described by 
Narasimhan [Narasimhan S] and Kowalski [Kowalski RP].  
First, E. coli strain IM08B17 was grown overnight on sheep blood agar plates (Becton 
Dickinson, Heidelberg, Germany) at 35°C. Fresh grown IM08B colonies were picked with a 
cotton swab and were suspended in PAS (equivalent to a 4.5 McFarland turbidity standard). 
This suspension was pipetted onto the surface of non-nutrient agar plates, and was spread out 
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using an L-shaped spreader. 
In a second step, 2 x104 cysts were mixed with 100 µl PBS in absence and presence of one of 
the antiamoebic agents (0.02% PHMB, 0.02% CH, 0.1% HD, 0.1% PD, 0.1% DD, 5% NM, 
0.0065% MF, 1% PVPI), and were incubated at 30°C for 2 hours in a Thermomixer 
(Eppendorf AG) with a shaking rate of 650 rpm. Thereafter, 10 µl of the cell suspensions was 
transferred into fresh tubes, was mixed with 10 µl trypan blue solution (0.4%) and was 
incubated for 5 minutes at room temperature. 980 µl PBS was subsequently added to each 
tube (the drugs were diluted 100 folds) and the cells were carefully suspended by pipetting 
gently up and down. Then, 50 µl of the stained cell suspensions (100 cells) was pipetted into 
the middle of the non-nutrient agar E. coli plates, and the suspension was desiccated for 
around 10 minutes. As a next step, circles were drawn on the bottom of the plates to confine 
the borders of the Acanthamoeba cyst solution, and bright field images of these regions were 
taken. A. castellanii inoculated plates were incubated upside up for 24 hours at 30°C.  
Thereafter, plates were sealed by parafilm (Pechiney, Menasha, USA) and were incubated 
upside down for up to 5 weeks at 30°C.  
As a negative control, cysts were incubated in 100 µl PBS (without antiamoebic agents) for 2 
hours. As a positive control, cysts were incubated in lysoform (Rossmann GmbH, Berlin, 
Germany) for 2 hours.  
Bright field images were taken with a Leica DMI4000 B microscope every 24 hours until 72 
hours, then every week until the end of the 5th week, using a 10-fold magnification. These 
experiments (with each antiamoebic agent) were repeated five times on different days. 
 
2.4.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7.02, by one- or two-way ANOVA 
tests, followed by Dunnett’s or Sidak’s multiple comparisons tests. P≤0.05 was considered as 
statistically significant.  
One-way ANOVA test was used to make a comparison between groups with different 
antiamoeabic agents. Then, the Dunnett's multiple comparison test was used to compare each 
group (3 different antiamoebic agent concentrations for each drug) to controls. For Ce6-PDT, 
the two-way ANOVA test was used, to compare groups with and without illumination, then 
the Didak's multiple comparisons test was applied to compare groups with 3 different 
concentrations. 
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3 RESULTS 
3.1 Histological analysis of Acanthamoeba keratitis eye 
globes 
Images of the histological analysis are shown at figures 4. 
There was no central corneal epithelium on the analysed globes. We could not observe 
Acanthamoeba trophozoites or cysts neither in the cornea (Figures 4 A and B) nor in other 
ocular tissues. There was one corneal endothelial cell per field of view (original magnification 
40x) analyzing the first and no corneal endothelial cells examining the second case. 
There were anterior synechiae in the chamber angle of both cases and lymphocytic infiltration 
around the central retinal artery and vein, associated with fibrous metaplasia of the retinal 
pigment epithelium (Figures 4 C-E). 
Additionally, we observed perivascular inflammatory cell infiltration (mainly lymphocytes) in 
the episclera and around ciliary nerves, analysing the first case (Figure 4A). This was 
associated with non-granulomatous uveitis, cilioschisis and tractional retinal detachment. 
Cross sections of the optic nerve revealed gliosis and optic nerve atrophy. 
Histopathologic studies of the second case revealed a multifocal, non-granulomatous 
choroiditis with lymphocytic infiltration (Figure 4E). 
 
 
Figure 4. Histological images of both cases. In the first case (A and B, haematoxylin-eosin), 
Acanthamoeba trophozoites or cysts were not detectable in the corneal or other ocular tissues, but 
lymphocytic infiltration of the episclera (arrow) and choroidal detachment (long arrow) were 
shown. In the first case (C, haematoxylin-eosin), perivascular lymphocytic infiltration (arrow) and 
retinal atrophy (long-arrow) and perivascular lympocytic infiltration around central retinal artery 
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was detectable (D, haematoxylin-eosin). In the second case, there was lymphocytic infiltration of 
the choroid (E, haematoxylin-eosin). 
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3.2 Human corneal cell cuture experiments 
A part of this dissertation (chapters 2.2, 3.2 and 4.2 as much as 
Summary/Zusammenfassung on human cells) have been published in “Shi L, Stachon T, 
Seitz B, Wagenpfeil S, Langenbucher A, Szentmáry N. The effect of antiamoebic agents on 
viability, proliferation and migration of human epithelial cells, keratocytes and endothelial 
cells. Curr Eye Res 2018; 43: 725-33.”. To use data of this publication for this doctoral 
dissertation was approved by Current Eye Research. 
 
Epithelial cell, keratocyte and endothelial cell viability, proliferation and migration using 
different concentrations of PHMB, CH, DD, HD and PD are displayed at figures 5-7. 
Viability and proliferation data are displayed using boxplots (including median, 25% and 75% 
quartile as well as 95% confidence interval) grouped by concentration and drug, and 
migration data are displayed grouped by time interval and drug.  
 
 




Figure 5. Human corneal epithelial cell (HCEC), keratocyte and human corneal endothelial cell 
(HCEC-12) viability, using different dibromopropamidine-isethionat (DD), propamidin isethionat 
(PD), hexamidine-diisethionat (HD), polyhexamethylen biguanid (PHMB) and chlorhexidine (CH) 
concentrations. 100% represents viability of controls. Data are displayed with boxplots (including 
median, 25% and 75% quartile as well as 95% confidence interval) grouped by concentration and 
drug. The maximal concentrations used were 0.1% for HD and DD, and 0.02% for PHMB and CH. 
The maximal concentration for PD was 0.0125% (1/8 of 0.1% Brolene® eye drop concentration, 
as the eye drops had to be diluted with culture medium). Thereafter, all solutions underwent a 
serial two fold-dilution. 
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Figure 6. Human corneal epithelial cell (HCEC), keratocyte and human corneal endothelial cell 
(HCEC-12) proliferation, using different dibromopropamidine-isethionat (DD), propamidin 
isethionat (PD), hexamidine-diisethionat (HD), polyhexamethylen biguanid (PHMB) and 
chlorhexidine (CH) concentrations. 100% represents proliferation of controls. Data are displayed 
with boxplots (including median, 25% and 75% quartile as well as 95% confidence interval) 
grouped by concentration and drug. The maximal concentrations used were 0.1% for HD and DD, 
and 0.02% for PHMB and CH. The maximal concentration for PD was 0.0125% (1/8 of 0.1% 
Brolene® eye drop concentration, as the eye drops had to be diluted with culture medium). 
Thereafter, all solutions underwent a serial two fold-dilution.  
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Figure 7. Migration of epithelial cells (HCEC) and endothelial cells (HCEC-12) in 24 hours 
using 3.9x10-4 % (1/256) dibromopropamidine-isethionat (DD), 3.9x10-4 % (1/256) propamidin 
isethionat (PD), 3.9x10-4 % (1/256) hexamidine-diisethionat (HD), 7.8x10-5 % (1/256) 
polyhexamethylen biguanid (PHMB) and 7.8x10-5 % (1/256) chlorhexidine (CH) concentrations 
and migration of keratocytes in 24 hours using 7.8x10-4 % (1/128) DD, 7.8x10-4 % (1/128) PD, 
7.8x10-4 % (1/128) HD, 1.6x10-4 % (1/128) PHMB and 1.6x10-4 % (1/128) CH concentrations. 
The area of the gap is displayed. Data are displayed with boxplots (including median, 25% and 75% 
quartile as well as 95% confidence interval) grouped by time interval and drug. Cell cultures 
without drugs were used as controls. 
 
 
Images of the gap (migration assay) using HCEC, keratocytes and HCEC-12 at different 
timepoints (0, 6, 9, 12 and 24 hours following scratch by yellow pipette tips) in control cell 
cultures are shown in figure 8. 
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Figure 8. Images of the gap are shown at different timepoints (0, 6, 9, 12 and 24 hours following 
scratching by yellow pipette tips) in control cell cultures. The area of the gap was calculated as a 
percentage, compared to the size of the area directly after scratching. Different cell types have 
shown different cell growth speed.  
 
Using the Kruskal-Wallis test, all diamidines and biguanides had a significant overall effect 
on HCEC, keratocyte and HCEC-12 viability (p=0.001; p=0.001; p=0.003). 
The “area under the curve” (AUC) using different anti-Acanthamoeba drugs is displayed in 
figure 9. 
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Figure 9. Epithelial cell (HCEC), keratocyte and endothelial cell (HCEC-12) viability “area under 
curve” (AUC) for hexamidine diisethionat (HD), propamidin isethionate (PD), 
dibromopropamidine diisethionat (DD), polyhexamethylen biguanid (PHMB) and chlorhexidine 
(CH). CH and PD, with the highest viability AUC for all cell types are marked with green circle.  
 
 
Using a Mann-Whitney test, there was a significant difference in viability AUC of HCEC, 
keratocytes and HCEC-12 comparing PD and PHMB (p≤0.014 for all; PD better) or 
comparing PD and HD (p≤0.011 for all; PD better). There was a significant difference in 
viability AUC of keratocytes and HCEC-12 comparing CH and HD (p≤0.027; CH better), and 
in viability AUC of HCEC-12 comparing PD and HD (p=0.005; PD better) and viability AUC 
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  PHMB CH DD HD 
CH 
HCEC 0.014    
Keratocyte 0.057    
HCEC-12 0.054    
DD 
HCEC 0.686 1.0   
Keratocyte 1.0 1.0   
HCEC-12 1.00 0.151   
HD 
HCEC 1.0 0.123 1.0  
Keratocyte 1.0 0.027 1.0  
HCEC-12 1.00 0.004 1.0  
PD 
HCEC 0.001 1.0 0.131 0.011 
Keratocyte 0.014 1.0 0.322 0.006 
HCEC-12 0.002 1.0 0.005 <0.001 
 
Table 3. Analysis of epithelial cell (HCEC), keratocyte and endothelial cell (HCEC-12) viability 
„area under curve” (AUC) for hexamidine diisethionat (HD), propamidin isethionate (PD), 
dibromopropamidine diisethionat (DD), polyhexamethylen biguanid (PHMB), chlorhexidine (CH) 
with Mann-Whitney test. Significant p values are bold. In case of statistically significant 
difference in viability AUC, the drug with better (higher) viability AUC is marked in green. 
 
Using the Kruskal-Wallis test, all diamidines and biguanides had a significant overall effect 
on HCEC and keratocyte proliferation (p=0.022; p=0.001), but they had no significant overall 
effect on HCEC-12 proliferation (p=0.167). Therefore, a non-parametric Mann-Whitney 
U-test was used to compare proliferation AUC values between pairs of drugs for HCEC and 
keratocytes, but not for HCEC-12. 
The “area under the curve” (AUC) for HCEC and keratocytes using different 
anti-Acanthamoeba drugs is displayed in figure 10. Using a Mann-Whitney test, there was a 
significant difference in proliferation AUC of HCEC, comparing PD with PHMB, CH, DD, 
HD (mean 2.36 vs 3.11, 3.02, 3.02, 2.97; PD worse for all) (p≤0.016 for all). 
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Figure 10. Epithelial cell (HCEC) and keratocyte proliferation “area under curve” (AUC) for 
hexamidine diisethionat (HD), propamidin isethionate (PD), dibromopropamidine diisethionat 
(DD), polyhexamethylen biguanid (PHMB) and chlorhexidine (CH). PHMB and CH with the 
highest proliferation AUC for both cell types are marked with green circle.  
 
Using a Mann-Whitney test, there was a significant difference in proliferation AUC of 
keratocytes, comparing PHMB with HD, PD (mean 2.92 vs 2.12, 2.07; PHMB better for both) 
(p=0.004; p=0.002), comparing CH with HD, PD (mean 3.06 vs 2.12, 2.07; CH better for both) 
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  PHMB CH DD HD 
CH 
HCEC 1.0    
Keratocyte 1.0    
DD 
HCEC 1.0 1.0   
Keratocyte 1.0 0.684   
HD 
HCEC 1.0 1.0 1.0  
Keratocyte 0.004 0.001 0.076  
PD 
HCEC 0.002 0.007 0.008 0.016 
Keratocyte 0.002 <0.001 0.043 1.0 
 
Table 4. Analysis of epithelial cell (HCEC) and keratocyte proliferation „area under curve” (AUC) 
for hexamidine diisethionat (HD), propamidin isethionate (PD), dibromopropamidine diisethionat 
(DD), polyhexamethylen biguanid (PHMB), chlorhexidine (CH) with Mann-Whitney test. 
Significant p values are bold. In case of statistically significant difference in proliferation AUC, 
the drug with better (higher) proliferation AUC is marked in green. 
 
Using the Kruskal-Wallis test, all diamidines and biguanides had a significant overall effect 
on keratocyte migration (p=0.006), but they had no significant overall effect on HCEC and 
HCEC-12 migration (p=0.657; p=0.178). Therefore, a non-parametric Mann-Whitney U-test 
was used to compare migration AUC values between pairs of drugs for keratocytes, but not 
for HCEC and HCEC-12. 
The “area under the curve” (AUC) using different antiamoebic drugs is displayed in figure 
11. 
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Figure 11. Keratocyte migration “area under curve” (AUC) for controls, hexamidine diisethionat 
(HD), propamidin isethionate (PD), dibromopropamidine diisethionat (DD), polyhexamethylen 
biguanid (PHMB) and chlorhexidine (CH). PD, the highest migration AUC (slower migration) is 
marked with green circle. 
 
Using a Mann-Whitney test, there was a significant difference in migration AUC of 
keratocytes comparing PD with control, PHMB, CH, DD and HD (mean 2.93 vs 2.37, 2.49, 
2.43, 2.32, 2.51; PD worse for all) (p≤0.012). However, no significant difference was noted 
when comparing keratocyte migration AUC of other pairs of drugs (p=1.0 for all) (Table 5). 
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  PHMB CH DD HD PD 
CH Keratocyte 1.0     
DD Keratocyte 1.0 1.0    
HD Keratocyte 1.0 1.0 1.0   
PD Keratocyte 0.012 0.003 <0.001 0.020  
Control Keratocytes 1.0 1.0 1.0 1.0 <0.001 
 
Table 5. Analysis of keratocyte migration „area under curve” (AUC) for control, hexamidine 
diisethionat (HD), propamidin isethionate (PD), dibromopropamidine diisethionat (DD), 
polyhexamethylen biguanid (PHMB), chlorhexidine (CH) with Mann-Whitney test. Significant p 
values are bold. In case of statistically significant difference in migration AUC, the drug with 
better (lower) migration AUC is marked in green.   
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3.3 Comparison of assays to study the effectiveness of 
antiparasitics against Acanthamoeba castellanii trophozoites 
and cysts  
3.3.1 LDH release assay 
In order to confirm the antiamoebic potentials of the drugs PHMB (0.02%), PD (0.1%), and 
MF (0.0065%) on Acanthamoeba trophozoites [Narasimhan S; Kowalski RP; Sunada A], a 
series of LDH release assays were carried out (Figure 12). All antiamoebic agents induced a 
significant release of LDH into the supernatants of the drug-challenged trophozoite cultures 
when compared to the unchallenged control group (p<0.0001), in line with previous studies 
reporting that all three drugs exhibited a significant cytotoxicity on Acanthamoeba 
trophozoites [Siddiqui R 2016]. Based on the LDH release values, MF was identified as the 
most effective drug of this test panel causing a significantly higher LDH release than PD 
(p=0.0011) and PHMB (p<0.0001). PD was significantly more effective in releasing LDH 
than PHMB (p=0.0004).  
As the lysis buffer supplied by the CytoTox 96® Non-Radioactive kit could not lyse 1BU 
cysts, we could not set a maximum LDH release control for these and we could only perform 
LDH assay for 1 BU trophozoites.  
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Figure 12. Cytotoxic effect of 0.02% PHMB, 0.1% PD and 0.0065% MF, on 1BU trophozoites 
and cysts, using trypan blue assay (n=3) and on 1BU trophozoites, using LDH assay (n=5).  
Trypan blue assay: 0.02% PHMB, 0.1% PD and 0.0065% MF had a significant cytotoxic effect on 
1BU trophozoites and cysts (p<0.0001). 0.1% PD and 0.0065% MF had a significantly higher 
cytotoxic effect on 1BU trophozoites, than 0.02% PHMB (p<0.0001). There was no significant 
difference between 0.1% PD and 0.0065% MF cytotoxicity for 1 BU trophozoites (P=0.0608).  
The cytoxic effect on 1BU cysts was significantly less using 0.0065% MF, than 0.02% PHMB or 
0.1% PD (P<0.0001). However, there was no significant difference between cytotoxic effect of 
0.02% PHMB and 0.1% PD, observing 1BU cysts (P=0.9883) 
LDH assay: 0.0065% MF was significantly more cytotoxic than 0.1% PD (p=0.0011) and 0.02% 
PHMB (p<0.0001), and 0.1% PD was significantly more cytotoxic than 0.02% PHMB (p=0.0004), 
observing 1BU trophozoites. 
 
3.3.2 Trypan blue assay 
The effects of PHMB, PD and MF on the viability of 1BU cells were next determined with a 
trypan blue exclusion assay [Strober W], which monitors the integrity of cell membranes 
(Figure 12, and the corresponding phase-contrast images of Figures 13 and 14). In untreated 
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1BU trophozoites and cysts (controls) we observed only a small proportion of cells that 
displayed a relevant blue staining. Following trypan blue staining, about 3.7 ± 1.8% of the 
drug-free trophozoites and 2.1 ± 0.2% of the cysts displayed a clear blue signal. Challenging 
1BU cells with PHMB clearly increased the ratios of blue stained cells to 59.3 ± 1.5% 
(trophozoites) and 100% (cysts), respectively. This effect was even stronger when 1BU cells 
were challenged with PD and MF, respectively. The latter drug increased the ratios of blue 
stained cells to 100% (trophozoites) and 77.7 ±5.1% (cysts), while almost all PD-treated 1BU 
trophozoites/cysts became trypan blue positive (Table 6). When drug-challenged cysts were 
screened for blue staining intensities, some differences between drugs were noticed. 
Challenging cysts with PD yielded a highly homogeneous trypan blue staining pattern with all 
cysts displaying mean grey values >95%. However, when the cysts were treated with MF and 
PHMB, respectively, a more heterogeneous staining pattern was observed. MF and PHMB 
produced small proportions of blue stained cysts that showed lower grey values (3.45% with 
85%-90%, 6.90% with 90%-95%, and 89.65% with >95% mean grey value for PHMB, and 
9.1% with 90-95%, and 90.9% with >95% mean grey value for MF).  
 
Table 6. Percentage of trypan blue, Hoechest 33342, calcein-AM and ethidium homodimer-1 
positive 1BU trophozoites and cysts, with and without antiamoebic agent treatment. Hoechest 
33342, calcein-AM and ethidium homodimer did not stain untreated trophozoites and cysts 
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Figure 13. Trypan blue, Hoechest 33342, calcein-AM and ethidium homodimer-1 staining of 
1BU trophozoites, with and without antiamoebic agent treatment. Hoechest 33342, calcein-AM 
and ethidium homodimer-1 did not stain untreated trophozoites. 
Trypan blue stained 3.6%, Hoechest 33342 100%, ethidium homodimer-1 100%, calcein-AM 
75.33% of 0.02% PHMB treated trophozoites. Following 0.1% PD treatment, Hoechst 33342 and 
ethidium homodimer-1 were 100%, trypan blue 59.33%, calcein-AM 9.67% positive in 
trophozoites. 0.0065% MF exposure resulted in 100% Hoechst 33342 and 100% ethidium 
homodimer-1, 95.67% trypan blue and in 0% calcein-AM positivity of trophozoites. 
 
Figure 14. Trypan blue, Hoechest 33342, calcein-AM and ethidium homodimer-1 staining of 
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1BU cysts, with and without antiamoebic agent tretament. Hoechest 33342, calcein-AM and 
ethidium homodimer-1 did not stain untreated cysts. 
Trypan blue stained 100%, Hoechest 33342 100%, ethidium homodimer-1 100%, calcein-AM 
60.67% of 0.02% PHMB treated cysts. Following 0.1% PD treatment, Hoechst 33342 and 
ethidium homodimer-1 were 100%, trypan blue 99.33%, calcein-AM 36.67% positive in cysts. 
0.0065% MF exposure resulted in 77.67% trypan blue, 100% Hoechst 33342 and 100% ethidium 
homodimer-1 and in 0% calcein-AM positivity of cysts. 
 
3.3.3 Fluorescent staining 
Drug treated trophozoites and cysts and healthy controls were mixed either with Hoechst 
33342 or a combination of calcein-AM and ethidium homodimer-1, and fluorescence images 
were taken as outlined in Materials and Methods. Representative fluorescence images of 
Hoechst 33342 and calcein-AM/ethidium homodimer-1 treated cells are displayed in Figures 
12 and 13, respectively, and percentages of Hoechst 33342, calcein-AM and ethidium 
homodimer-1 positive trophozoites/cysts are given in (Table 6). Notably, neither Hoechst 
33342 nor the calcein-AM/ethidium homodimer-1 mixture stained drug-free trophozoites and 
cysts. However, this changed when 1BU cells were challenged with the antiamoebic drugs. 
Hoechst 33342 and ethidium homodimer-1 stained 100%/100% of the PHMB treated 1BU 
cells blue and red, respectively, and calcein-AM stained 75.3±4.0%/60.7±3.5% of the PHMB 
challenged trophozoites/cysts green. Following PD treatment, Hoechst 33342 and ethidium 
homodimer-1 were 100%/100% positive in trophozoites/cysts, and calcein-AM stained 
9.7±2.5%/36.7±4.5% of the PD treated trophozoites/cysts green. Similarly, MF exposure 
yielded in 100%/100% Hoechst 33342 and ethidium homodimer-1 stained trophozoites/cysts. 
However, none of the MF treated 1BU trophozoites/cysts emitted relevant amounts of green 
fluorescence upon exposure to light of the wavelength 490 nm. 75.3±4.0%/60.7±3.5% of the 
PHMB challenged trophozoites/cysts were positive for both ethidium homodimer-1 and 
calcein. Similar results were observed with PD treated 1BU cells, which were in 9.7±2.5% 
(trophozoites) and 36.7±4.5% (cysts) positive for both calcein and ethidium homodimer-1.  
 
3.3.4 Non-nutrient agar E.coli plate assay  
In drug free controls, 1BU trophozoites appeared within 24 hours including central and 
peripheral areas of the agar plate. After 72 hours, a considerable amount of trophozoites could 
be seen (Figure 15). After 5 weeks of cultivation, a number of cysts appeared in central and 
peripheral parts of the agar plate in controls. Notably, a similar kinetic was observed with MF 
treated trophozoites (Figure 15). Although MF can diminish the trophozoite amount (Figure 
13) and result in the highest amount of LDH release (Figure 12), the surviving cells are still 
viable.  
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However, when PHMB and PD treated 1BU trophozoites were spotted onto the non-nutrient 
agar E. coli plates, respectively, and monitored for growth and encystment, a more cohesive 
picture to those seen with the afore mentioned assays emerged (Figure 15). Small, strange 
shaped structures appeared on central and peripheral parts of the agar plate after 72 hours of 
cultivation (Figure 16). Nevertheless, after 5 weeks of cultivation, no fresh cysts were 
observed at central or peripheral parts of the agar plate.  
When PHMB and PD treated trophozoites were monitored after 5 weeks of growth on 
non-nutrient agar E. coli plates, no fresh cysts were found at the central or peripheral parts of 
the agar plates (Figure 15).  
When drug treated cysts were tested with the non-nutrient agar E. coli assay, the following 
observations were made (Figure 16): in the control and the MF treated 1BU cyst groups, 
trophozoites became visible on central and peripheral parts of the agar plate after 24 hours of 
cultivation (Figure 16).  
A different picture emerged, when PHMB and PD treated cysts were tested with this assay 
(Figure 16). In both drug treated groups, irregularly shaped, smaller trophozoites with a 
thinner cell wall appeared after 72 hours in the central and peripheral parts of the agar plates, 
which did not form cysts again within the 5 weeks of monitoring.  
 
RESULTS                                               49 
  
 
Figure 15. Phase-contrast images of 1BU trophozoites on non-nutrient agar E. coli plates, 0 and 
72 hours and 5 weeks following 0.02% PHMB, 0.1% PD and 0.0065% MF treatment and trypan 
blue staining. In controls and in 0.0065% MF treated 1BU trophozoites groups, new trophozoites 
appeared outside than marked circle after 72 hours, and encystment could be observed following 5 
weeks. In 0.02% PHMB and 0.1% PD treated 1BU trophozoites groups, strange shaped 
trophozoites appeared after 72 hours (arrows), which did not form cysts following 5 weeks. The 
strange trophozoites were smaller and thinner compared to the normal trophozoites 
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Figure 16. Phase-contrast images of 1BU cysts on non-nutrient agar E. coli plates, 0 and 72 
hours and 5 weeks following 0.02% PHMB, 0.1% PD and 0.0065% MF treatment and trypan blue 
staining. In controls and in 0.0065% MF treated 1BU cyst groups, trophozoites appeared after 72 
hours, and encystment could be observed following 5 weeks. In 0.02% PHMB and 0.1% PD 
treated 1BU cyst groups, strange shaped trophozoites appeared after 72 hours (arrows, see also 
Figure 17), which did not form cysts following 5 weeks. The strange trophozoites were smaller 
and thinner compared to the normal trophozoites. 
 
After 5 weeks of incubation, the appearance of roundish but flat cells with a discontinuous 
wall (sometimes double-wall) was noticed in the PD and PHMB treated cyst groups (Figure 
17). The amount of these irregularly shaped structures increased over time and was also 
observed in the central and peripheral parts of the agar plates.  
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. 
Figure 17. In 0.02% PHMB and 0.1% PD treated 1BU cyst groups, strange shaped structures 
appeared after 72 hours, which did not form cysts again following 5 weeks. The strange 
trophozoites were smaller and thinner compared to the normal trophozoites. 
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3.4 Efficacy of antiamoebic agents and Ce6-PDT against 
Acanthamoeba castellanii 1-BU  
3.4.1 LDH assay  
Results of the LDH assay for trophozoites (n=5) are displayed in figure 18.  
PHMB, CH, HD, PD, DD, NM, MF, and chlorin e6-PDT increased LDH activity significantly 
in trophozoite cultures (P<0.01), compared to controls.  
The use of Ce6 without illumination did not change LDH activity (P=0.96), compared to Ce6 
with illumination. There was no LDH activity difference between groups with different Ce6 
concentration, but without illumination (P=0.09). Illumination alone did not increase LDH 
activity significantly (P=0.96), compared to controls. 
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Figure 18. Cytotoxic effect (mean ± standard error) of polyhexamethylen biguanid (PHMB), 
chlorhexidine (CH), hexamidine-diisethionat (HD), propamidin-isethionate (PD), 
dibromopropamidine-diisethionat (DD), natamycin (NM), miltefosine (MF), and chlorin e6 
photodynamic therapy (PDT) on 1BU trophozoites (LDH assay; n=5).  
PHMB, CH, HD, PD, DD, NM, MF, and chlorin e6-PDT increased LDH activity significantly in 
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trophozoite cultures (P<0.01), compared to controls. The use of Ce6 without illumination did not 
change LDH activity (P=0.96), compared to Ce6 with illumination. („*”: P≤0.05; „**”: P≤0.011; 
„***”: P≤0.005) 
 
3.4.2 Trypan blue assay 
Cytotoxicy of different agents, using trypan blue assay is shown in figures 19 and 20.  
All used drugs increased percentage of trypan blue stained 1BU trophozoites significantly 
(P<0.01), compared to controls. Concerning different drug concentrations, all increased 
cytotoxicity on 1BU trophozoites significantly (P<0.01) compared to controls, except 0.005 % 
PHMB (P=0.59), 0.005 % CH (P= 0.10) and Ce6 without illuminaton (P=0.99). Illumination 
alone (P=0.99) or the use of different Ce6 concentrations without illumination (P=0.09) did 
not increase trypan blue positivity, compared to controls. 
All used drugs increased percentage of trypan blue stained 1BU cysts significantly (P<0.01), 
compared to controls. Concerning different drug concentrations, all increased cytotoxicity on 
1BU cysts significantly (P<0.01) compared to controls, except 0.005 % CH (P=0.29), Ce6 
without illumination (P=0.94), 0.00095% or 0.0038% Ce6 with illumination (P=0.14; P=0.06) 
and illumination alone (P=0.94). 
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Figure 19. Cytotoxic effect (mean ± standard error) of polyhexamethylen biguanid (PHMB), 
chlorhexidine (CH), hexamidine-diisethionat (HD), propamidin-isethionate (PD), 
dibromopropamidine-diisethionat (DD), miltefosine (MF), povidone iodine (PVPI) and chlorin e6 
photodynamic therapy (PDT) on 1BU trophozoites (trypan blue assay; n=3).  
All used drugs increased percentage of trypan blue stained 1BU trophozoites significantly 
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(P<0.01), compared to controls. Concerning different drug concentrations, all increased 
cytotoxicity on 1BU trophozoites significantly (P≤0.02) compared to controls, except 0.005 % 
PHMB (P=0.59), 0.005 % CH (P= 0.10) and Ce6 without illuminaton (P=0.99). („*”: P≤0.05; 
„**”: P≤0.011; „***”: P≤0.005) 
 
 
Figure 20. Cytotoxic effect (mean ± standard error) of polyhexamethylen biguanid (PHMB), 
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chlorhexidine (CH), hexamidine-diisethionat (HD), propamidin-isethionate (PD), 
dibromopropamidine-diisethionat (DD), miltefosine (MF), povidone iodine (PVPI) and chlorin e6 
photodynamic therapy (PDT) on 1BU cysts (trypan blue assay; n=3).  
All used drugs increased percentage of trypan blue stained 1BU cysts significantly (P<0.01), 
compared to controls. Concerning different drug concentrations, all increased cytotoxicity on 1BU 
cysts significantly (P<0.01) compared to controls, except 0.005 % CH (P=0.29), Ce6 without 
illumination (P=0.94) and 0.00095% or 0.0038% Ce6 with illumination (P=0.14; P=0.06). („*”: 
P≤0.05; „**”: P≤0.011; „***”: P≤0.005). 
 
3.4.3. Non-nutrient agar E.coli plate assay 
Images of the non-nutrient agar E. coli plate at the center and periphery of the plates at three 
different time-points are displayed at figure 21.  
Following excystment, in all plates, remnants of the original cysts remained observable at the 
same place during the complete follow-up.  
In lysoform treated control group, no trophozoites or fresh cysts emerged during follow-up.  
In control, 0,1% DD and 5% MF groups, fresh, normal-shaped trophozoites appeared after 
24-72 hours and the trophozoites could move out from the center to the peripheral area of the 
plate. In these groups, encystment happened again after 1 week.  
In 0.02% PHMB, 0.1% PD, and 1% PVPI groups, normal shaped trophozoites could not be 
observed after 24-72 hours (for all 5 repeat experiments). No fresh cysts appeared during 
follow-up in these groups.  
In the 5% NM groups, NM was deposited on the plates like powder, which made 
differentiation of NM powder and acanthamoeba difficult under light-microscopy. However, 
in 0.1% HD and 5% NM groups, we observed the same phenomenon as for control, 0,1% DD 
and 5% MF groups (see above) in 1 of 5 repeat experiments. In the other 4 of 5 experiments, 
the same phenomenon as for 0.02% PHMB, 0.1% PD or 1% PVPI groups was observed (see 
above). 
In 0.02% CH group, treated cysts behaved similarly to control, 0,1% DD and 5% MF groups 
(see above) in 2 of the 5 repeat experiments. In the other 3 of 5 experiments, the same 
phenomenon as for 0.02% PHMB, 0.1% PD or 1% PVPI groups (see above) was observed.
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Figure 21. Images of the non-nutrient agar E. coli plate assay (following inocuation of cysts), at 
the center and periphery of the plates at three different time-points.  
In lysoform treated positive control group, no trophozoites or fresh cysts emerged during 
follow-up. 
In control and 0.0065% MF groups, normal-shaphed fresh trophozoites appeared from 24 hours 
(see central and periphreal areas at 72 hours and 5 weeks, arrows) and the trophozoites could 
move out from the central area of the plate (see peripheral images at 72 hours and 5 weeks, 
arrows). In these groups, encystment happened again from 1 week (see central and peripheral 
images at 5 weeks, bold arrows).  
In 0.02% CH, 0.1% HD and 1% PVPI groups, we observed strange-shaped structures after 24-72 
hours. No fresh round cysts appeared during follow-up.  
At the 5% NM images we also see the „natamycin-suspension”, which made differentiation of NM 
and acanthamoeba difficult. There were no new cysts during 5 weeks (see peripheral images at 72 
hours and 5 weeks). However, some spherical structures could be observed (arrows).  
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4 DISCUSSION 
4.1 Histological analysis of Acanthamoeba keratitis eye 
globes 
In 2007, Awwad et al. reported chronic chorioretinal inflammation with perivascular 
lymphocytic infiltration and diffuse neuroretinal ischemia as a new potentially blinding 
syndrome in 4 of 5 enucleated eyes after AK [Awwad ST]. In 4 of these patients, there were 
Acanthamoeba cysts in the cornea, nevertheless, the posterior segment of the eye failed to 
demonstrate Acanthamoeba cysts or throphozoites. Burke et al. had reported similar results in 
one patient in 1992 [Burke JP].  
Most interestingly, we observed episcleritis, non-granulomatous uveitis with choroidal and 
central retinal artery/vein lymphocytic infiltration (vasculitis) and neuroretinal degeneration, 
without presence of Acanthamoeba throphozoites or cysts in the cornea or other ocular tissues, 
in two enucleated eyes of two patients. 
Extracorneal invasion of Acanthamoeba had in the literature only been described in 8 patients 
between 1975 and 2013. In three of these cases, scleral invasion and in 5 others 
Acanthamoeba sclerokeratitis have been described. Iovieno et al. reported 18.5% occurrence 
of sclerokeratitis in their case series with presence of degraded necrotic cysts in scleral nodule 
biopsy of these patients [Iovieno A 2014]. They considered sclerokeratitis as a 
T-cell-mediated immune response, which requires systemic immunosuppression [McClellan 
K; Lee GA]. Acanthamoeba antigens elicit an immune response that leads to generation of T 
cell clones. These T cell clones then cross-react with antigens expressed in the normal eye, 
which may lead to the generation of additional T cell clones by a process called “epitope 
spreading” [Cornaby C].  
We hypothesize that lymphocytes are more efficient than neutrophils and macrophages to 
chemo attract Acanthamoeba. But on the other hand, it can induce an immune response, 
which may also destroy other structures of the eye.  
Lee has reported, that corneal antigen presenting cells can reside in the central cornea, migrate 
to the cervical lymph nodes and activate T-cells [Lee HS]. These T-cells then trigger an 
inflammatory reaction in the vascularized ocular tissues, such as uvea and retina. Interestingly, 
Johns at al. reported on chorioretinitis without vitritis in the contralateral eye of an 
immunocompetent AK patient, which might have been a regional immune-related 
inflammation, induced by local tissue infection through Acanthamoeba [Johns KJ 1988b]. 
There is another hypothesis that Acanthamoeba may induce a state of autoimmunity through 
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molecular mimicry via corneal antigen presenting cells or a type III immune reaction, which 
may target vascular receptors leading to vasculitis and thrombosis. 
In our cases, there was retinal artery occlusion in one patient and retinal vein occlusion in the 
second patient, before enucleation. Histopathological examination found lymphocytic 
infiltration of these vessels. This may indicate a possible local immune-mediated vasculitis 
with secondary thrombosis and occlusion. We hypothesize that the peripheral vasculitis might 
be rather related to reactive inflammation than to the Acanthamoeba itself. This could have 
happened similarly in three patients reported by Awwad et al. [Awwad ST] and Burke at al. 
[Burke JP]. 
Interestingly, necrotizing vasculitis, leukocytoclastic vasculitis, thrombosis of small vessels 
and thrombo-occlusive vasculitis have also been described in systemic Acanthamoeba-related 
diseases, such as cutaneous Acanthamoeba infections and Acanthamoeba encephalitis. 
There are only 4 case reports on Acanthamoeba in the posterior part of the eye. Jones et al. 
described a case in a 7-year-old boy with meningoencephalitis, with throphozoites in the 
ciliary body [Jones DB]. Heffler et al. reported on Acanthamoeba cysts in the aqueous humor 
and in the vitreous in a patient with acquired immune deficiency syndrome [Heffler KF]. In 
both patients, chrorioiditis and retinal vasculitis were present. Moshari et al. found 
Acanthamoeba cysts and throphozoites in the human retina, without chronic choroidal and 
retinal perivascular inflammation [Moshari A]. Mammo et al. report a recurrent 
Acanthamoeba infection presenting initially as keratitis, followed by retinitis and 
histolopathology-confirmed endophthalmitis [Mammo Z]. 
Interestingly, Clarke et al. showed that the clearance of the anterior chamber happens within 
15 days following injection of Acanthamoeba trophozoites to the anterior chamber of hamster 
eyes [Clarke DW]. This was supported through a robust neutrophilic reaction in these eyes. 
This also supports the hypothesis, that choroid and retinal inflammation is rather 
immune-mediated and not related to the presence of Acanthamoeba. However, there might be 
a difference in human an animal immune response. 
Previous studies have shown that polyhexamethilen-biguanide and propamidin-isethionat may 
be cytotoxic for human corneal cells in clinically relevant concentrations. [Shi L] It has also 
been suggested, that posterior segment inflammation may be related to toxicity of topical 
treatment used in AK. However, previous studies also reported AK patients with long-lasting 
topical treatment and absence of posterior pole inflammation, which contradicts this theory. 
Nevertheless, mature cataract formation in both patients could be related to toxicity of 
biguanides. These can then disrupt the lens surface, provoke lenticular oxidative or osmotic 
stress, and contribute to cataract formation by altering lipid membranes, damaging lens fibers, 
and inducing electrolyte imbalance [Ehlers N; Herz NL].  
In our study, enucleation was performed at the end of patient histories with repeat (intraocular) 
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surgeries. The most conspicious finding of the histological analysis is that there were no 
trophozoites or cysts in both enucleated eyes. Although there were Acanthamoeba 
trophozoites and cysts in the explanted corneal buttons of PKPs and repeat PKPs previously, 
these were not persisting in corneal and ocular tissues subsequently. However, intraocular 
inflammation with central retinal artery/vein occlusion developed. Therefore, we hypothesize 
that Acanthamoeba or the long lasting triple-therapy trigged an immune response, which was 
persisting without microorganisms. 
In long-standing, recalcitrant Acanthamoeba keratitis, uveitis, retinal vasculitis and scleritis 
may occur and result in blindness, even without further persistence of Acanthamoeba 
trophozoites or cysts. The etiology of these inflammatory complications is unclear, but may 
be explained with molecular mimicry or type III immune-reaction. Therefore, in late stage of 
Acanthamoeba keratitis, systemic immune suppression may be necessary for a longer period 
of time. 
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4.2 Human corneal cell cuture experiments 
A part of this dissertation (chapters 2.2, 3.2 and 4.2 as much as 
Summary/Zusammenfassung on human cells) have been published in “Shi L, Stachon T, 
Seitz B, Wagenpfeil S, Langenbucher A, Szentmáry N. The effect of antiamoebic agents on 
viability, proliferation and migration of human epithelial cells, keratocytes and endothelial 
cells. Curr Eye Res 2018; 43: 725-33.”. To use data of this publication for this doctoral 
dissertation was approved by Current Eye Research. 
 
To the best of our knowledge, this is the first comparative study on the effect of diamidines 
and biguanides on human epithelial cells, keratocytes and endothelial cells. In AK, the cysts 
can reach close to the endothelium [Hager T]. Therefore, an effective drug must penetrate all 
corneal layers. To obtain information on the effect of diamidines and biguanides on corneal 
cells, cells of all corneal layers were analyzed in these experiments.  
In our present study we have demonstrated that PD decreases human cell viability less than 
DD and HD, whereas CH decreases viability less than PHMB. Diamidines reduce 
proliferation of human epithelial cells and keratocytes more than biguanides, and propamidin 
isethionate reduces migration of keratocytes. 
The genus Acanthamoeba is classified into 19 different genotypes including T1 to T19 based 
on rRNA gene sequence analysis. T4 genotypes are typically associated with human AK, but 
non-T4 genotypes have also been identified as pathogenic strains of AK [Iovieno A 2010; 
Arnalich-Montiel F]. However, correlation between agent effectiveness and Acanthamoeba 
genotype has not been verified until now [Sunada A; Wright P; Brasseur G]. Therefore, based 
on current literature, clinicians have no means to decide for or against the use of a specific 
diamidine or biguanide depending on Acanthamoeba genotype.  
From the diamidine group, propamidine (Brolene®) was considered not to have an excellent 
cystcidal effect [Sunada A] and hexamidine (Hexacyl®) has higher amebicidal activity than 
propamidine [Perrine D]. However, as the percentage of trophozoites and cysts in the cornea 
is currently not objectively measurable, clinicians also cannot base their decision (preferred 
topical therapy) on an objectibe measure. 
PHMB (Lavasept ®) is known to interact with membrane phospholipids, affecting membrane 
fluidity and conformation thus leading to ionic leakage and cell death. CH (Curasept®) is 
positively charged and ionizing with the negatively charged plasma membrane of the 
Acanthamoeba, resulting in structural and permeability changes, ionic leakage, and 
cytoplasmic disruption causing cellular damage and cell death of Acanthamoeba.  
Comparing biguanides and diamidines clinically, literature on the in vitro cysticidal effect of 
biguanides and diamidines is controversial [Lee JE; Arnalich-Montiel F; Khunkitti W; 
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Kowalski RP; Lim N ]. Some authors describe biguanides as having the most promising effect 
against Acanthamoeba in vitro, particularly against the highly resistant cyst form of the 
organism [Lee JE; Dart JK]. The use of PHMB and CH has been described as effective 
cysticidal monotherapy or combination therapy against different Acanthamoeba strains [Lee 
JE; Mafra CSP; Moon EK; Mathers W]. In contrast, Sunada et al. observed only a weak 
cysticidal effect of PHMB [Sunada A]. Some other reports have considered PHMB equivalent 
or more effective than CH against trophozoites and cysts of different Acanthamoeba species. 
Conversely, some studies report CH as more effective. [Narasimhan S; Turner NA]  
Turner studied biocide susceptibility during the differentiation process of Acanthamoeba 
castellanii and observed that the time of emerging resistance during encystment varies for 
different biocides [Turner NA]. Resistance to minimal amoebicidal concentrations of PHMB 
and PD occurred 24 hours after initiation of the encystment process. Resistance to CH 
developed during 36 hours. The smaller molecular size of CH compared with PHMB may 
contribute to the prolonged uptake of the biguanide derivative in immature cysts. 
After a systematic database review summarizing all of the available clinical data in 2015, 
Alkharasi et al. concluded that there is insufficient evidence to evaluate the relative 
effectiveness and safety of medical therapy for the treatment of AK [Alkharasi M]. Results 
yielded no difference with respect to outcomes reported (resolution of disease, visual acuity, 
need for keratoplasty, adverse events) between chlorhexidine and PHMB. However, the 
sample size was inadequate to detect clinically meaningful differences between both.  
Which diamidine or biguanide is more effective in vitro or in the clinical practice against 
Acanthamoeba trophozoites and cysts, is not yet proven. Therefore, it is important to evaluate 
the safety and potential toxic effect on human corneal cells. To date there is only limited 
information in the literature on the effect of diamidines and biguanides on human corneal 
cells. 
Moon et al. could not verify a cytopathic effect on HCEC using 0.02% PHMB for 30 minutes, 
in vitro [Moon EK]. In contrast, using the same PHMB concentration for 24 hours, no viable 
HCEC were seen in our experiments. Lee et al. determined similar to our findings, that 
PHMB damages keratocytes more than CH [Lee JE]. In contrast, and interestingly, CH used 
alone tended to be more cytotoxic than PHMB analyzing human umbilical vein endothelial 
cells (HUVEC), since CH induced cell necrosis and PHMB cell apoptosis. [Mafra CSP]  
Fernández-Ferreiro et al. described PD to be more cytotoxic on primary keratocytes than CH 
[Fernández-Ferreiro A]. In contrast, there was no significant difference in viability AUC 
comparing PD vs CH for HCEC, keratocytes and HCEC-12 in our study, but PHMB resulted 
in significantly worse viability AUC than PD for all human corneal cell types. 
 
There is also limited information in the literature on in vivo effects of biguanides on the 
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cornea. Vontobel et al. tested the effect of 0.02% PHMB and CH on rabbit corneas and found 
that none of them penetrated through the cornea to the anterior chamber [Vontobel SF]. In 
contrast, Murthy et al. observed absence of epithelial cells, loss of keratocytes with apparent 
apoptosis and loss of endothelial cells after 0.02% chlorhexidine use [Murthy S]. Shigeyasu  
described limbal stem cell deficiency, corneal neovascularization, cataract formation and 
endothelial cell loss following exposure of the ocular surface to 20% chlorhexidine 
[Shigeyasu C] . Other case reports linked corneal necrosis, iris atrophy, cataract formation and 
ischemic ocular inflammation to 0.02% chlorhexidine use [Murthy S; Ehlers N; Awwad ST]. 
Concerning diamidines, some authors describe mild epithelial keratopathy in the form of 
epithelial microcysts or superficial punctate keratitis [Johns KJ 1988a; Duguid IG]. following 
the use of propamidine. On the other hand, Herz et al. and Ehlers & Hjordtal reported on 
rapidly progressive cataract and iris atrophy during propamidine isethionate or hexamidine 
diisethionate treatment [Herz NL; Ehlers N]. However, these clinical changes could also be 
related to the AK itself or to the effect of topical corticosteroids used. 
In summary, PD decreases human cell viability less than DD and HD, whereas CH decreases 
viability less than PHMB. Our results suggest that propamidin-isethionate as diamidine and 
chlorhexidin as biguanide should be used in order to reduce the cytotoxicity of 
antiacanthaemoeba treatment on human epithelial cells, keratocytes and endothelial cells. 
Diamidines reduce proliferation of human epithelial cells and keratocytes more than 
biguanides and propamidin isethionate reduces migration of keratocytes. Therefore, although 
propamidin isethionate is less cytotoxic than other diamidine, its negative effect on cell 
proliferation and migration indicates that its application should not be extended in patients.  
A limitation of our study is that cell cultures were analyzed, and, therefore, our experience 
might not completely correspond to results of an in vivo analysis. A multicenter, randomized 
clinical trial could further clarify advantages and disadvantages of the use of diamidines and 
biguanides in the treatment of AK. 
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4.3 Comparison of in vitro assays to study the effectiveness 
of antiparasitics against Acanthamoeba castellanii 
trophozoites and cysts 
In order to compare the efficacy of different antiamoebic agents, survival of Acanthamoeba 
trophozoites and cysts have to be observed. Up-to date the use of trypan blue assay [Lee X; 
Siddiqui R 2017], calcein-AM-ethidium homodimer staining [Chen Z], 
5-cyano-2,3-tetrazolium chloride (CTC) staining [Mito T] and observation of treated 
Acanthamoeba on agar plate [Narasimhan S; Kowalski RP] or in fresh medium [Kobayashi T 
2011; Kobayashi T 2012, Mito T; Baig AM] have been described in the literature. 
Nevertheless, all these examination methods have pitfalls, especially with difficulties in using 
an appropriate negative control.  
As a first step, in our present work, the XTT assay was used to determine the efficacy of 
antiamoebic agents (data not shown). This assay measures the activity of mitochondria in the 
living cells to reduce the tetrazolium salt XTT to orange-colored compounds of formazan. 
Previously, Moss [Moss BJ] and Loures [Loures FV] used the XTT assay to estimate 
metabolic activity of fungi. Although it has recently been described, that NAD(P)H 
dehydrogenase has a similar function in plants, fungi and Acanthamoeba castellanii 
mitochondria [Antos-Krzeminska N], our trophozoite cultures did not show a positive XTT 
assay, even after the use of antiamoebic agents (data not shown). 
As a next step, we used the LDH assay, to evaluate percentage of dead Acanthamoeba. LDH 
is an enzyme found in nearly all living cells, with a half-life time of approximately 9 hours. 
LDH is released during tissue damage. Most interestingly, during our measurement series, 
LDH release was the highest using 2 hours incubation time for all antiamoebic agents, but 
there was no LDH release after 24 hours of incubation. Therefore, we suggest that the LDH 
release peak of 1BU trophozoites is after 2 hours incubation time and subsequently, LDH is 
degraded. 
Using the LDH assay, all antiamoebic agents had a significant cytotoxic effect on 1BU 
trophozoites, but 0.0065% MF shown a significantly higher effect as both other drugs, and 
1BU count through 0.0065% MF was relatively reduced. This might be explained through a 
lytic effect of miltefosine on trophozoites with more LDH release, but has to be proven in 
further experiments. 
The effects of PHMB, PD and MF on the viability of 1BU cells were next determined with a 
trypan blue exclusion assay [Strober W], which monitors the integrity of cell membranes 
(Figure 12, and the corresponding phase-contrast images of Figures 13 and 14). Living cells 
possess intact cell membranes that exclude penetration of certain dyes, such as trypan blue, 
DISCUSSION                                              67 
  
eosin, propidium, whereas dead cells do not. This is true for human cells, funghi [McMahon 
TA] and plant cells [van Wees S].  
The results in our experiments also suggested in untreated 1BU trophozoites and cysts 
(controls) that these cells featured compromised cell membranes/cyst walls. However, 
challenging 1BU cells with the antiamoebic drugs clearly increased the number of trypan blue 
positive cells for all three drugs tested (Figure 12 and Table 6). Challenging 1BU cells with 
PHMB clearly increased the ratios of blue stained cells to 59.3 ± 1.5% (trophozoites) and 100% 
(cysts), respectively, suggesting that the membranes/cyst walls of the majority of PHMB 
treated cells became permeable for trypan blue by this drug. This effect was even stronger 
when 1BU cells were challenged with PD and MF, respectively. These findings are basically 
in line with the LDH release assay results (Figure 12), suggesting that all tested drugs exerted 
highly significant cytotoxic effects on 1BU cells, with PD and MF displaying very strong 
effects on trophozoites, while PHMB was significantly less effective in destabilizing 
trophozoites membranes (Figure 12). PHMB and PD exerted the strongest cytotoxic effect on 
cysts, while MF was significantly less effective against cysts (Figure 12).  
The impact of the antiamoebic drugs on cell viability of A. castellanii trophozoites and cysts 
were next tested with a small set of fluorescent dyes. Hoechst 33342 is a cell permeable blue 
fluorescent dye that is specific for DNA and can be used to stain the nuclei of viable and fixed 
cells [Crowley LC; Eddaoudi A]. The cell permeable vital stain calcein-AM is a 
non-fluorescent derivative of the green fluorescent dye calcein, which can be converted to 
calcein due to the activity of cytosolic esterases [Romano V]. The vital stain is often used in 
combination with ethidium homodimer-1, a cell impermeable DNA-specific red-fluorescent 
dye that stains nuclei of dead cells [Chan LL].  
Chen et al. determined the proportions of live/dead Acanthamoeba following photodynamic 
therapy, but their publication does not display the control group [Chen Z]. Notably, in our 
experiments, neither Hoechst 33342 nor the calcein-AM/ethidium homodimer-1 mixture 
stained drug-free trophozoites and cysts, indicating that both cell permeable dyes are not 
readily taken up and/or converted to a fluorescent dye by both A. castellanii growth stages.  
However, this changed when 1BU cells were challenged with the antiamoebic drugs. The fact 
suggested that the membranes or cyst walls of the PHMB and PD challenged 1BU cells were 
sufficiently compromised to allow the diffusion of ethidium homodimer-1 into the cells but 
were viable enough to convert calcein-AM to calcein. A. castellanii cysts contain sufficient 
amounts of active non-specific esterases to cleave the acetoxymethyl esters from the 
non-fluorescent calcein derivative to generate a fluorescent probe. Concerning MF, the results 
indicate that MF treated A. castellanii trophozoites and cysts cannot convert the 
non-fluorescent calcein derivative calcein-AM to the green fluorescent calcein. We suggest 
that it might be because MF affects Acanthamoeba cystoplasm.  
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The afore mentioned enzyme- and cell permeability based viability assays suggested that the 
antiamoebic drugs PHMB, PD, and MF can kill significant amounts of, if not all, A. 
castellanii trophozoites and cysts under in vitro conditions. In order to confirm that these high 
killing rates suggested by the afore mentioned assays are real, a non-nutrient agar E. coli plate 
assay was next carried out, in which trophozoites were fed on an E. coli lawn. This assay also 
allows to monitor whether drug challenged cysts can still germinate in a growth favoring 
environment, and if cysts can be formed once the E. coli lawn was consumed by viable 
trophozoites. In this assay, untreated and drug challenged trophozoites/cysts were stained by 
trypan blue and subsequently placed in the center of a non-nutrient agar plate inoculated with 
a layer of viable E. coli cells, and the germination of cysts and the growth of trophozoites was 
monitored over time by light microscopy. Representative phase-contrast images of 1BU 
trophozoites and cysts that were cultivated for 0, 3, and 35 days on non-nutrient agar E. coli 
plates are shown in Figures 15 and 16. For both 1BU trophozoites and cysts, the trypan blue 
staining disappeared within 24 hours and, therefore, a follow-up of the fate of trypan blue 
positive Acanthamoebae beyond this time frame was not possible.  
The results in MF challenged trophozoites were the same as in the drug free control group, 
indicating that MF neither substantially affected the ability of trophozoites to migrate on the 
agar plate, nor was encystment markedly affected (Figure 15). Although MF can diminish the 
trophozoite amount (Figure 13) and result in the highest amount of LDH release (Figure 12), 
the surviving cells were still viable. A. castellanii 1BU cysts can also germinate on 
non-nutrient agar E. coli plates and migrate on the agar, and that these abilities were not 
markedly affected by the MF treatment. Chambers & Thompson reported that empty cysts 
will be left after excystment, which can be distinguished by scanning electron microscope 
[Chambers JA]. Unfortunately, we were unable to determine the percentage rates of 1BU 
excystment, as empty cysts were not clearly distinguishable from filled cysts by our light 
microscopy approach. After 5 weeks of cultivation, cysts could be observed in the central and 
peripheral parts of the agar plates, showing that MF treated cysts did not lose their excystment 
and encystment abilities (Figure 16). 
When put into relation with the trypan blue assay results and the calcein-AM/ethidium 
homodimer-1 stainings (Figures 12 and 13), one can furthermore come to the conclusion that 
a positive staining of 1BU trophozoites for trypan blue or ethidium homodimer-1 does not 
allow to state that all these cells are dead. This conclusion is also strengthened by the findings 
that considerable amounts of PD and PHMB treated 1BU trophozoites were also positive for 
calcein, indicating that these cells were intact enough to allow the conversion of calcein-AM 
to calcein. In addition, PHMB and PD treated trophozoites released a lower LDH amount. 
Nevertheless, the high percentage of trypan blue positive PHMB and PD treated trophozoizes 
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may refer to a damage of the cell membrane, which may also be the reason of their inability to 
form normal shaped trophozoites and encyst again.  
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4.4 Efficacy of antiamoebic agents and Ce6-PDT against 
Acanthamoeba castellanii 1-BU 
There are controversial literature data on effectivity of different drugs against Acanthamoeba 
isolates in vitro and in vivo. We aimed to analyze the effect of nine potential antiamoebic 
agents on Acanthamoeba castellanii trophozoites and cysts in vitro, using LDH assay, trypan 
blue staining and non-nutrient E. coli agar plate assay. With these methods we planned to get 
a better insight into the potential specific treatment against the 1BU Acantahmoeba castellanii 
isolate.  
PHMB and CH belong to biguanides and are membrane-acting agents. Literature on their in 
vitro cysticidal effect is controversial. Some authors describe them as the most promising 
agents against different Acanthamoeba strains in vitro, particularly against the highly resistant 
cyst form of the organism [Mathers W; Lee JE, Moon EK]. In contrast, Sunada et al. observed 
weak cysticidal effect of PHMB [Sunada A]. Some other reports have considered PHMB 
equivalent or more effective than CH against trophozoites and cysts of different 
Acanthamoeba species. Some other studies, however, have reported CH as more effective 
[Narasimhan S; Turner NA].  
Diamidines are nucleic acid-acting drugs. PD (Brolene®) was considered not to have an 
excellent cysticidal effect [Sunada A] and HD (Hexacyl®) was described to have higher 
amoebicidal activity than PD. [Perrine D] Also the efficacy of PD was considered lower than 
that of CH or MF against Acanthamoeba [Yamazoe K; Polat ZA 2012].  
5% natamycin is known to inhibit fungal growth by binding to sterols and by impairment of 
membrane fusion via perturbation of ergosterol-dependent priming reactions that precede 
membrane fusion [te Welscher YM]. A case report described complete healing of AK within 
two months, using 2% natamycin [Jackson TN]. Sunada determined an excellent cysticidal 
effect of 5% natamycin [Sunada A].  
MF is an intracellular targeting agent, which can denature essential cell proteins, and disrupt 
the cell membrane. MF was used successfully in amoebic encephalitis [Aichelburg AC] and in 
several in vitro experiments against Acanthamoeba [Walochnik J 2009; Polat ZA 2012; Polat 
ZA 2014].  
PVPI is a broad spectrum microbicide that destroys microbial protein and DNA [Bigliardi PL, 
2017]. 1% PVPI can cause ridges of the outer cyst wall and separation of the inner cysts wall 
from the outer one [Sunada A] and seemed to be effective against Acanthamoeba in vitro 
[Yamasaki K; Gatti S]. 
With increasing resistance of microorganisms to antibiotics, photodynamic therapy (PDT) 
may be one potential treatment option [Szentmáry N 2018]. Crosslinking as PDT alone 
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seemed not to be effective enough in AK [Hager T; del Buey MA; Makdoumi K]. 
Nevertheless, PDT using Ce6 and red light seemed to be effective in the treatment of 
Pseudomonas aeruginosa keratitis [Wu MF, Deichelbohrer M]. Obviously, the photosensitizer 
uptake through the microorganism and availibilty of oxygen seems to be decisive in treatment 
efficacy and this is extremely difficult in case of double-walled Acanthamoeba cysts [Winkler 
K; Chen Z].  
Concerning the overall effect of the drugs, in our experiments, PHMB, CH, HD, PD, DD, NM, 
MF, and chlorin e6-PDT increased LDH activity and trypan blue positivity significantly in 
trophozoites (P<0.01), compared to controls. All used drugs also increased percentage of 
trypan blue stained 1BU cysts significantly (P<0.01), compared to controls, all clinically used 
concentrations of the drugs were significantly increasing trypan blue positivity of trophozoites 
and cyst (P<0.01). Concerning different drug concentrations, the effect of 0.005% PHMB 
(P=0.59) and 0.005% CH (P= 0.10) on trophozoites was weaker compared to other 
concentrations and the effect of 0.005% CH (P=0.29), 0.00095% or 0.0038% Ce6 with 
illumination (P=0.14; P=0.06) on cysts was lower than other applied concentrations, using the 
trypan blue assay. These results proof the potential of the clinically used drug concentrations 
but the ineffectivity of Ce6-PDT against acanthamoeba cysts. 
It is well known, that Acanthamoeba cysts have a double cellulose wall, which is extremely 
resistant to enviromental damage. Using trypan blue assay, all drugs had significant 
cytotoxicity on Acanthamoeba trophozoites and cysts. To better understand the behaviour of 
trophozoites and cysts, we inoculated them after treatment to non-nutrient agar E.coli plates, 
which served as nutrition for the Acanthamoeba. In our opinion, the most striking 
observations could be made analyzing these plates. 
In DD and MF groups, similar to controls, normal-shaped trophozoites with migratory 
potential appeared after 24-72 hours and encystment could happen again from 1 week. In 
PHMB, CH, HD, PD, NM and PVPI groups, there were no normal-shaped trophozoites after 
24-72 hours and cysts could not be formed again during 5 weeks (figure 21). PHMB, PD and 
PVPI seemed to be even more effective in repeat experiments than CH, HD and NM against 
the Acanthamoeba castellanii 1-BU strain, as PHMB, PD and PVPI were effective in all 5 
experiments against the 1BU strain, however, CH, HD and NM only in 3 or 4 of 5 repeat 
experiments. 
Our experiments show, that 1BU Acanthamoeba castellanii was more vulnerable to PHMB, 
CH, HD, PD, NM and PVPI treatment than to DD and MF. However, none of these could 
completely eradicate trophozoites and cysts.  
In summary, PHMB, CH, HD, PD, NM and PVPI seem to be more effective against 
Acanthamoeba castellani 1BU strain, than DD and MF. In vitro analysis of treatment efficacy 
of different antiamoebic agents, especially the non-nutrient agar Eschericia coli plate assay 
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may provide us information on specific treatment of different Acanthamoeba strains in the 
future. 
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4.5 Conclusions and outlook to the future 
Acanthamoeba keratitis is a severe, sight threatening infection.  
Acanthamoeba keratitis patients at the early stage of the disease suffer from tearing and ocular 
pain. At this time-point, the ophthalmologists observe a relative mild ophthalmological status, 
compared to the pronounced discomfort of the patient. A pseudodendritiformic epitheliopathy, 
“dirty epithelium”, typically spot-like multifocal stromal infiltrates and radial perineuritis can 
be observed at this stage. Later on, a Wessely immune ring (ring infiltrate) develops. In 
long-standing, recalcitrant Acanthamoeba keratitis, uveitis, retinal vasculitis and scleritis may 
occur and result in blindness, even without further persistence of Acanthamoeba trophozoites 
or cysts. The etiology of these inflammatory complications is unclear, but may be explained 
with molecular mimicry or type III immune reaction. Therefore, in late stage of 
Acanthamoeba keratitis, systemic immune suppression may be necessary for a longer period 
of time. 
 
Since AK presents with heterogeneous clinical appearance and low incidence, there have been 
no clinical trials comparing different treatment modalities in this disease and no standardized 
treatment of AK has been established, yet.  
The lack of a standardized therapy against AK is also in part due to the lack of a generally 
agreed drug testing regime against Acanthamoeba. Although a number of staining methods 
and viability tests have been already used to test the efficacy of drugs against Acanthamoeba 
isolates in vitro, a routine method, to enable a specific treatment in AK, against the isolated 
Acanthamoeba, is still not available. 
 
Analysing human corneal cells, PD decreases human cell viability less than DD and HD, 
whereas CH decreases viability less than PHMB. Considering these effects of antiamoebic 
agents on human corneal cells, we suggest the use of propamidin-isethionate as diamidine and 
chlorhexidin as biguanide in order to reduce the cytotoxicity of antiamoebic treatment on 
human epithelial cells, keratocytes and endothelial cells. Diamidines reduce proliferation of 
human epithelial cells and keratocytes more than biguanides and propamidin isethionate 
reduces migration of keratocytes. Therefore, although propamidin isethionate is less cytotoxic 
than other diamidines, its negative effect on cell proliferation and migration indicates that its 
application should not be extended in patients. A multicenter, randomized clinical trial could 
further clarify advantages and disadvantages of the use of diamidines and biguanides in the 
treatment of AK. 
 
Acanthamoeba species can develop two life-forms, trophozoites and cysts. To be effective 
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against these protozoan pathogens a drug should also attack the dormant cyst state of the 
pathogen, and as a consequence, efficacy of an antiamoebic drug should be evaluated with 
both life-forms. We tested a number of common enzymatic- and dye-based viability assays to 
study the killing efficacies of antiamoebic drugs against A. castellanii 1BU trophozoites and 
cysts. When compared with the non-nutrient agar E. coli plate assay, which served as 
gold-standard in this comparison, none of the enzymatic- and dye-based assays tested here 
yielded results with both life-forms that were comparable with the results obtained with the 
culture-based method. Discrepancies were especially evident with the drug MF, which 
yielded almost no effect on the viability of 1BU trophozoites and cysts when assayed with the 
culture-based method, while all enzymatic- and dye-based assays tested here suggested a 
good to excellent killing efficacy of this drug to at least one of the life-forms of this pathogen. 
These findings suggest that commonly used viability assays such as trypan-blue staining and 
life-dead staining with calcein-AM and ethidium homodimer-1 may - depending on the drug - 
overestimate the killing efficacy of the antiamoebic agent, while the culture-based 
non-nutrient agar E. coli plate assay proofed to be a reliable method to study the drug efficacy 
of antiamoebic agents against both life-forms of this protozoan pathogen. 
 
Based on the culture-based non-nutrient agar E. coli plate assay, we have shown, that 
Acanthamoeba castellanii 1BU strain was more vulnerable to PHMB, CH, HD, PD, NM and 
PVPI treatment than to DD and MF. However, none of these could completely eradicate 
trophozoites and cysts. The non-nutrient agar Eschericia coli plate assay may provide us 
information on specific treatment of different Acanthamoeba strains.  
The limitation of our study is that we included only one Acanthamoeba isolate for our 
experiments. In subsequent studies, different Acanthamoeba isolates - especially clinical 
isolates from AK patients - should be tested, in order to enable a more specific treatment for 
AK patients, in the long-term.  
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